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Abstract 
Axillary lymph node (ALN) metastasis status is an important prognostic marker in 
breast cancer and is widely employed for tumour staging and defining an adjuvant 
therapy. In an attempt to avoid invasive procedures which are currently employed for 
the diagnosis of nodal metastasis, several markers have been identified and tested for 
the prediction of ALN metastasis status in recent years. However, the nonlinear and 
complex relationship between these markers and nodal status has inhibited the 
effectiveness of conventional statistical methods as classification tools for 
diagnosing metastasis to ALNs. The aim of this study is to propose a reliable 
artificial neural network (ANN) based decision support system for ALN metastasis 
status prediction. ANNs have been chosen in this study for their special 
characteristics including nonlinear modelling, robustness to inter-class variability 
and having adaptable weights which makes them suitable for data driven analysis 
without making any prior assumptions about the underlying data distributions.  To 
achieve this aim, the probabilistic neural network (PNN) evaluated with the .632 
bootstrap is investigated and proposed as an effective and reliable tool for prediction 
of ALN metastasis. For this purpose, results are compared with the multilayer 
perceptron (MLP) neural network and two network evaluation methods: holdout and 
cross validation (CV).  A set of six markers have been identified and analysed in 
detail for this purpose. These markers include tumour size, oestrogen receptor (ER), 
progesterone receptor (PR), p53, Ki-67 and age. The outcome of each patient is 
defined as metastasis or non-metastasis, diagnosed by surgery.  This study makes 
three contributions: firstly it suggests the application of the PNN as a classifier for 
predicting the ALN metastasis, secondly it proposes a the .632 bootstrap evaluation 
of the ANN outcome, as a reliable tool for the purpose of ALN status prediction, and 
thirdly it proposes a novel set of markers for accurately predicting the state of nodal 
metastasis in breast cancer.  Results reveal that PNN provides better sensitivity, 
specificity and accuracy in most marker combinations compared to MLP. The results 
of evaluation methods’ comparison demonstrate the high variability and the 
existence of outliers when using the holdout and 5-fold CV methods. This variability 
is reduced when using the .632 bootstrap. The best prediction accuracy, obtained by 
combining ER, p53, Ki-67 and age was 69% while tumour size and p53 were the 
most significant individual markers. The classification accuracy of this panel of 
markers emphasises their potential for predicting nodal spread in individual patients. 
This approach could significantly reduce the need for invasive procedures, and 
reduce post-operative stress and morbidity. Moreover, it can reduce the time lag 
between investigation and decision making in patient management.  
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Chapter 1 
1. Introduction  
1.1. Motivation  
Breast cancer is the major cause of cancer death amongst women and it has been 
identified as the most prevalent cancer type amongst women in England in 2009 
which afflicted 40,260 new women [1]. There has been a sharp decrease in breast 
cancer mortality in recent years due to the application of early surgery and systemic 
therapy such as chemotherapy or hormonal therapy for disease management [2]. 
However, besides reducing the mortality rate, these treatments cause various side 
effects such as patient morbidity and are a tremendous cost to treatment centres. In 
order to reduce the patient morbidity and treatment costs as well as mortality, it is 
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important to both avoid unnecessary treatment and not to miss cancer-positive cases. 
Diagnosis of cancer-positive patients is especially important as successful cancer 
management through adjuvant therapies
1
 and surgery is significantly improved by 
early diagnosis.   
Early diagnosis, identifying patients who need treatment and defining the adjuvant 
therapy depends on many factors including axillary lymph nodes (ALNs) metastasis 
(cancer cells present in the ALNs), tumour size, menopausal status, presence of 
hormone receptors and abnormal production of certain proteins such as HER2/neu in 
tumour. Amongst these factors, the presence of tumour in the ALNs and the 
corresponding number of involved nodes are regarded as the most important factors 
affecting the medical decision made for adjuvant therapy and surgery in patients with 
breast carcinoma [3-5].   
For many years, the presence of ALN metastasis has been diagnosed by axillary 
dissection. Nevertheless, dissection is associated with marked morbidity and is 
unnecessary for patients with negative ALN metastasis. Sentinel lymph node biopsy 
(SLNB) is currently practiced widely in the United Kingdom as an alternative 
approach to axillary dissection [6]. SLNB is considered to be an accurate and reliable 
method for ALN sampling which causes less morbidity than axillary dissection, 
especially for women with node-negative breast cancer. However, SLNB is still an 
invasive procedure with its associated complications such as pain and paraesthesia 
[7].  
                                                 
1
 Adjuvant therapy in cancer refers to the treatment which is given in addition to surgery. 
Adjuvant therapies, such as chemotherapy, are advised where the initial tumour has been 
removed but there is still a statistical risk of relapse. In Latin "adjuvans" means to help and, 
particularly, to help reach a goal. 
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Fisher et al. have shown that identifying an adjuvant choice of treatment and disease 
management is highly dependent on the state of tumour dissemination and the 
chance of survival [8]. Although accurate and reliable detection of metastasis in the 
ALNs is viable through axillary dissection, an alternative non-invasive method for 
identifying the state of tumour dissemination has been keenly sought.   
Since there has been an observation of microscopic metastasis in early-stage breast 
cancer in a significant number of patients, novel prognostic markers have become 
the area of interest for breast cancer prognosis. Many studies, utilizing specialized 
markers of tumour, have proven that these markers can be utilized as an alternative 
to dissection for ALN metastasis prediction [9-11]. A large variety of these 
biomarkers and their prognostic value in different kinds of cancer have been 
explored to make an accurate prognosis about tumour progression to help physicians 
identify the best therapy for the disease. 
Many cellular and molecular markers have been identified to be clinically useful for 
early diagnosis of breast cancer. However, the large number of available biomarkers 
and the complex relation of these markers with the state of tumour progression have 
negated the efforts of medical experts for accurate breast cancer prognosis based on 
these markers. Hence, computational techniques have been attempted for an accurate 
and reliable prognosis based on these factors.  
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1.2. Problem statement  
Although axillary dissection and SLNB offer an accurate and reliable detection of 
ALN metastasis, a less invasive method for identifying the state of tumour 
dissemination is more favourable for both patients and medical centres in terms of 
cost, mortality and morbidity.  Several tumour biomarkers have been utilized as an 
alternative to dissection for ALN metastasis prediction [9-11]. Nevertheless, there is 
little agreement to date on a single or a combination of predictive markers for 
accurate nodal status prediction that can replace the conventional techniques such as 
SLNB [7]. Large number of available tumour characteristics, the nonlinear and 
complex relationship between markers and nodal involvement and small sample 
sizes available for analysis are the main issues hindering ALN prediction with 
tumour characteristics as an alternative to the invasive procedures. 
 
1.2.1. Abundance and complex nature of 
biomarkers 
Many clinical, pathological and molecular markers have been identified to be 
clinically useful for early diagnosis of breast cancer. However, the large number of 
available biomarkers and the complex relation of these markers with the state of 
tumour progression have negated the efforts of medical experts for accurate breast 
cancer prognosis based on these markers.  
In addition, many new prognostic factors demonstrate non-monotonic characteristics 
i.e. not constantly increasing or decreasing. The prognostic value of some markers 
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also depend on their interaction with other markers. Therefore it would be desirable 
to identify the prognostic value of the potential prognostic markers. Seker et al. [12] 
have employed a multilayer perceptron (MLP) for identifying the most and least 
significant prognostic factors for breast cancer survival analysis by extracting feature 
evaluation indices. However, they confirm a level of uncertainty on the obtained 
ranking of features.  
1.2.2. Data availability  
One major issue in cancer prediction using tumour characteristics is that data sets 
relating to cancer typically can contain a small number of patients in comparison 
with the number of measured variables.  This is often due to the high cost of 
extracting, i.e. detecting and measuring these markers and establishing the 
relationship between degrees of expression and disease progression over a period of 
time. This limitation results in two problems in classification. First, the classifier will 
learn the existing patterns in the population using only a small number of samples. 
Second, an estimate of the accuracy of the classifier for new data can only be 
performed using the same small data set.  
 
1.3. Computer aided diagnosis  
To address the above issues, a wide range of studies have investigated various 
statistical and artificial intelligence methods for the prediction of nodal involvement, 
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exploiting the ever-increasing number of biomarkers deemed to be effective in 
disease dissemination and metastasis.  
Statistical methods have been conventionally applied to the prognosis and 
classification of breast cancer. However, the inefficiency of these techniques in 
analysing the nonlinear interaction of tumour biomarkers has initiated the necessity 
for more accurate and complex classification models. This inefficiency originates 
from the intrinsic characteristic of statistical methods such as assumptions about 
underlying distribution of data and requiring large sample size in each output class 
[13].  
An alternative method which has been successfully employed in the field of medical 
diagnosis and prognosis is artificial neural network (ANN). It has been proven that 
ANN results in cancer detection and prediction are better or at least comparable to 
the results obtained from statistical methods. Burke et al. [14] have shown that the 
predictive accuracy of ANN for five-year survival prediction is significantly better 
than a statistical method such as principal components analysis (PCA), classification 
and regression trees and logistic regression (LR).  
It is reported that artificial neural networks (ANN) provide a powerful method of 
analysing the inherently complex nature of potential cancer proliferation markers 
[15, 16]. In breast cancer, ANN has proved to be a reliable tool for predicting 
metastasis to the ALNs, using tumour’s cellular markers [17]. Therefore, ANN’s 
ability to identify highly nonlinear relationships between markers makes it a versatile 
tool in evaluating the dissemination of tumour proliferation data. Previous studies 
have shown that ANNs outperform most traditional and modern statistical 
techniques such as LR [18] and discriminant analysis (DA) [19].  
7 
 
Among various ANN architectures, MLP has been the most widely used method for 
cancer prediction and prognosis [20-22]. The effectiveness of MLPs in breast cancer 
diagnosis has been evaluated using clinical, pathological and immunohistochemical 
data which recommend MLP as a powerful technique for cancer prediction [21]. 
Nevertheless, MLPs suffer from some common drawbacks including network 
complexity, and numerous network variables require random weight initialisation 
and have to be optimised. 
Another ANN architecture that has been found suitable for numerous applications in 
recent years is the probabilistic neural network (PNN). The PNN, first introduced by 
Specht in 1988 and 1990, is capable of defining decision boundaries exploiting 
Bayesian theory [23, 24]. This quality makes the PNN an effective technique for 
classification and pattern recognition tasks, especially when used for data sets 
containing samples adequately correlated to the associated class and well separated 
categories [25]. The PNN also trains faster than the MLP and requires fewer 
variables to be optimised. Although this method has been known for some time, it 
has only recently been identified as an effective classifier for cancer diagnosis and 
prediction [26, 27].  
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1.4. Aims and objectives 
The primary aim in this study is to make an original contribution to the development 
of neural network models for breast cancer prognosis in terms of predicting the state 
of ALNs involvement. The biomolecular data selection for predicting the nodal 
involvement status requires an accurate system.  Therefore, the second aim of the 
project is to choose a reliable error estimation method for the ANNs employed in this 
study.  
A further objective is to accurately identify the contribution of each biomarker 
considered in this study to the prediction process.  This is demonstrated by using the 
designed ANN to determine the potential of these markers and the most reliable 
prediction from the least costly set of markers. Thus the objectives are mapped out as 
follows: 
- to introduce a specifically designed ANN for predicting the state of 
nodal involvement in breast cancer; 
- to develop a reliable analysis of the estimation of the designed ANN 
error rate, which can offer more reliable error estimation for small 
sample size in breast cancer prediction; 
- to gain insight into the importance of breast cancer biomarkers and to 
define an original effective combination of patient information and 
tumour markers for predicting ALN metastasis in breast cancer. 
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1.5. Methodology and contributions  
In this study, the PNN is proposed as a classification platform to predict ALN 
metastasis in a group of patients suffering from breast cancer. The MLP is employed 
as a benchmark method to be compared against the PNN due to its frequent 
application in breast cancer prognosis. The results of the PNN are reported and 
compared against the results obtained from the MLP in terms of accuracy, sensitivity 
and specificity. Using two ANN architectures, it is intended to investigate various 
ways of using neural network models to extend traditional statistical models for 
cancer prognosis. These models are expected to provide better results than linear 
statistical methods as they would be able to model both non-linear effects of 
prognostic factors and interactions between them. 
Another aim of the study is to choose a reliable error estimation method for the 
ANNs employed in this research. For this purpose, the variance of predictions 
obtained by .632 bootstrap, 5-fold cross validation and holdout methods are 
computed and compared.  
To achieve insight into the importance of breast cancer biomarkers, a novel set of six 
biomarkers is proposed for the purpose of predicting the progression of breast 
carcinoma.  While the relationship between some of these markers and nodal 
metastasis is well established in medical literature, no information is available on the 
degree of effectiveness of combining these features for ALN metastasis prediction in 
breast cancer. These biomarkers are analysed for their predictive significance 
associated with metastasis to ALNs and include tumour size together with the 
following five markers: oestrogen receptor (ER), progesterone receptor (PR), p53, 
Ki-67 expression and age. The data relating to these markers has been obtained using 
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minimally invasive procedures in which a sample of tumour is removed by needle 
biopsy and is less invasive than SLNB [7]. A full factorial design is devised to 
consider different combinations of these markers. These combinations are then tested 
to find the most effective individual marker or combination set in nodal status 
prediction and to discover the existence of nonlinear inter-relations among these 
markers.  Thus, this work offers the opportunity to investigate the ability of each 
feature set in differentiating node negative from node positive tumours using two 
different ANN structures.  
Much research has been donated to the application of MLP structures in breast 
cancer prediction [17-20]. The reliability of resampling methods for error estimation 
in MLPs have also been investigated in some studies [28]. Nevertheless, no work has 
been done on the effectiveness of the PNN in breast cancer prediction using a 
reliable error estimation method. This research demonstrates that the complex 
classification problem of breast cancer prediction, which cannot be currently 
addressed by traditional research techniques, can be solved effectively by proper 
selection of biomarkers, the use of PNN as an apt choice of ANN architecture, and 
an appropriate selection of the PNN parameters and validation method. The problem 
chosen for this work is the prediction of ALN metastasis in breast cancer patients. 
The reason for this choice lies in the fact that this problem is one of the most 
complex problems in the field of pattern classification. The difficulty in carrying out 
research in this field is the large number of available tumour markers with a highly 
nonlinear relation to ALN status, in addition to the complex interrelations between 
these markers. This makes it difficult even for oncologists to predict nodal status 
from patient information. Moreover, the creation of an automated system would 
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provide a huge benefit to the hospital field, which is constantly looking to reduce 
costs and mortality caused by unnecessary breast dissection. 
The contributions of this study can be summarised as follow: 
- The application of the PNN as a classifier for predicting the ALN 
metastasis and confirming the superiority of the PNN over the 
conventionally employed MLP through the comparison of both 
methods via a reliable error estimation technique 
- Improving the reliability of error estimation for both the PNN and the 
MLP for breast cancer prediction using the .632 bootstrap technique  
- accurately predicting the state of ALN metastasis in breast cancer and 
determining an effective set of biomarkers for nodal status prediction  
One major drawback associated with the ANNs is that they are deemed as a black 
box which does not provide interpretable rules in the output. In recent years, many 
studies have focused on techniques to extract rules from ANNs [29, 30]. 
Nevertheless, this study focuses on addressing common deficiencies in previous 
ANN studies to obtain reliable results and a novel marker combination for predicting 
breast cancer metastasis to ALNs and the point is not toward extracting rules.   
This study presents the results of two ANN structures evaluated with the .632 
bootstrap estimator to determine a novel combination of tumour biomarkers for the 
prediction of ALN metastasis in breast cancer.  The presented results for the 
prediction potential of the biomarkers in conjunction with the methods described in 
this research may serve as the basis for automatic and non-invasive prediction of 
breast cancer metastasis. This should significantly decrease patient morbidity by 
12 
 
reducing the need for invasive procedures and decrease patient mortality by timely 
prediction of nodal metastasis. 
 
1.6. Thesis outline   
The overall organisation of this thesis is as follows: After the introduction, chapter 2 
is dedicated to a review of the statistical, machine learning and ANN methods 
previously employed for breast cancer prediction. This chapter gives details of the 
advantages and disadvantages of the statistical and machine learning methods and 
the reason they have not been effective in breast cancer prediction. It then introduces 
the foundations of ANNs and a literature of the most widely used ANN structures in 
breast cancer diagnosis. The ANN outcome evaluation and currently employed error 
estimation methods are also described. 
Chapter 3 introduces the biomarkers chosen in this study and the dataset 
characteristics, in addition to the biomarkers’ measurement methods and descriptive 
statistics. The medical literature of the chosen biomarkers will be explained to 
establish their individual role and application in predicting the breast cancer 
progression. The final section of this chapter includes the scatter plots and 
correlation coefficients of the tumour biomarkers and the cancer metastasis to 
demonstrate the nature and the degree of correlation between different biomarkers 
and metastasis. 
Chapter 4 starts with an explanation of the  MLP structure, its training algorithm and 
common issues in cancer studies. Then an in depth explanation of the PNN, its 
structure and training algorithm is detailed. The last section of the chapter describes 
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.632 bootstrap which is an error estimation method based on resampling. The applied 
methods in conjunction with the employed data set bring about a novel application of 
PNN in breast cancer prediction.  
Chapter 5 presents the experimental results of the study. In the first section of results, 
the method of .632 bootstrap error estimation is compared with the performance of 
holdout and 5-fold CV methods for both the PNN and the MLP. In the second 
section of results, the results achieved by the PNN and the MLP are applied to all 
marker combinations presented and are tabulated and analysed. Finally, the best 
results achieved by the PNN and the MLP are presented in a single table and 
compared against each other. 
Chapter 6 contains a discussion of the results including an analysis of the reliability 
of different error estimation methods, a comparison of two ANNs and an analysis of 
results in terms of biomarkers’ prediction potential. The last part of discussion is 
dedicated to explain how the disadvantages in previous studies have been addressed 
in this work. Finally the conclusions drawn from this study, the contributions of the 
research and possible future research directions in this field are detailed in chapter 7. 
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Chapter 2 
2. Statistical and classification    
methods for breast cancer 
prediction  
2.1. Introduction  
Clinical decision making is based on multiple symptoms and measurements obtained 
from the patient. Physicians make diagnosis considering these multiple factors 
acquired from the patient, assigning weights to each factor and choosing the most 
probable diagnosis. This is usually done unconsciously by the physician based on the 
relative importance of each factor [31]. Physicians typically obtain this knowledge 
through experience by examining several patients, making diagnosis and then 
comparing it with the actual outcome. Therefore, experienced physicians are more 
likely to make a correct diagnosis than the novices.  
However, there are situations that even an expert needs assistance to make the 
correct decision. This is especially true for cancer prediction as there is excessively 
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large number of factors discovered to be related to the outcome. In addition, the 
relation between many of these factors and the cancer outcome in terms of metastasis 
or survival is not completely revealed yet. Availability of experts is another issue 
which necessitates the use of decision support systems (DSS) for cancer prediction.  
DSSs offer numerous advantages in medical decision making by taking into account 
a large number of factors simultaneously such that the complex relationship between 
the factors and the cancer outcome can be distinguished. This brings a significant 
benefit to medical centres in terms of costs and availability of expert oncologists.  
There are different types of medical DSSs depending on their approach to data 
classification. The main methodologies employed in breast cancer prediction are 
statistical and machine learning methods [32] for which a literature survey is 
reported in this chapter. For this purpose, regression and discriminant analysis (DA) 
are explained as the most commonly applied statistical methods and decision tree 
(DT) as the most routinely employed machine learning method in breast cancer 
prediction. In addition, the advantages and disadvantages of these methods are 
detailed. This leads the discussion to the necessity of employing more sophisticated 
classification algorithms such as ANN for overcoming the shortcomings of statistical 
and machine learning methods such as assumptions about underlying distribution of 
data and requiring large sample size in each output class. 
After the literature survey on the statistical and machine learning methods employed 
in breast cancer prediction, the foundations of ANNs, how they are trained and their 
learning process are explained. Then, a comprehensive literature of ANN application 
in breast cancer prediction, its advantages, disadvantages and current problems are 
mentioned and analysed. This elucidates the main gaps in the applied ANN systems 
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to breast cancer prediction which forms the focus of the thesis and the topics to be 
tackled in the next chapters. 
 
2.2. Statistical methods in cancer prediction  
Conventional statistical methods used in breast cancer prediction are regression 
methods and DA. These methods are mainly employed for classification of patients 
into different outcome groups using a set of discriminatory factors. A history of 
these techniques, their principles, advantages and disadvantages are detailed below. 
2.2.1. Regression Models 
Regression is the most commonly used statistical method in medical studies. It is 
employed to model and assess the relationship between a single or a set of input and 
output variables. In regression analysis, inputs are described as predictors or 
independent variables, while the outputs are termed as predicted outcome or 
dependant variables.  
There are different regression models depending on the type and number of input 
and output variables and their relationship. Linear regression, models the input-
output relation with a straight line while in a curvilinear regression model, any 
function forming a curve line can be used for input-output modelling. Multivariate 
regression analysis can be employed in case of developing a model for multiple 
inputs with a single output.  
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After developing the regression model for a set of input and output variables, the 
model is assessed to study how well the model fits the data and whether it requires 
any modifications. In addition to predictive modelling, regression analysis can be 
utilised as an exploratory tool to understand the nature of relationship between 
multiple factors. This helps to verify any existing relationship between variables and 
to clarify the description of this relationship.  
Linear regression is the simplest form of regression analysis. As mentioned before, it 
describes the linear relation between a dependant and independent variables. Prior to 
linear regression, it is common to use another measure of linear relation, called 
correlation coefficient, to measure the linear dependency of two variables. 
Correlation coefficient does not consider any causal relationship between the 
variables and it merely quantifies the strength of the linear relation between them. 
In the following sections, correlation coefficient is explained followed by linear 
regression analysis. LR is then explained in detail including its model building, 
underlying assumptions and the interpretation of the fitted model.   
2.2.2. Correlation coefficient  
Correlation coefficient is a measure of linear dependency between two variables. It is 
commonly employed prior to linear regression to explore the existence of any linear 
relationship between the dependant and independent variables. The most commonly 
used method for quantifying the amount of linear dependency between two 
continuous variables, A and B, is Pearson’s Correlation Coefficient (PCC). PCC 
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represents the strength of linear association between two variables A and B by 
normalising their covariance with respect to their standard deviation SA and SB as: 
       
        
    
 
               
    
 ( 2.1 ) 
where μA and μB are the expected values of two random variables A and B. PCC 
assigns a number between -1 and 1 for the measure of linear dependency between 
variables. A positive value represents a positive linear relationship, while a negative 
one implies negative linear and 0 suggests no relationship between variables.  
The main characteristic of the PCC is its invariance to linear transformation of the 
variables A and B. This implies that for example, with variables being described 
as       , PCC between the two variables represent a perfect correlation of 1.  
2.2.3. Linear regression  
Linear regression describes the relationship between an independent variable   and a 
dependant variable   given a set of data points       . This relationship is expressed 
as a straight line of the form: 
              ( 2.2 ) 
where    and    are the regression coefficients describing the intersect and the line 
slope respectively. The term    is the error defined as the difference between the data 
point         and the regression line. Linear regression analysis is performed to 
estimate the unknown coefficients    and   . Least squares method is commonly 
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used for estimating coefficients to fit a regression line to the data. In this method, the 
aim is to minimise the sum of squared errors, i.e. finding the solution to the 
derivative of    
 : 
   
                 
 
 
   
 ( 2.3 ) 
Getting the derivative of    
  with respect to    and    leads to the following 
equations: 
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 ( 2.5 ) 
Solving the above equations with respect to the two unknown variables    and    
gives [33]: 
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 ( 2.7 ) 
The covariance and standard deviation (  ) definitions are defined as: 
                      
 
   
      
 
   
      ( 2.8 ) 
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 ( 2.9 ) 
where   and    represent the mean of the vectors   and   respectively. Using the 
covariance and standard deviation,   can be rewritten as: 
   
        
  
 ( 2.10 ) 
 Having   ,    is defined from ( 2.4 ) as: 
         ( 2.11 ) 
Quality of fitting the line to the data is then quantified and assessed by the 
correlation coefficient as defined in equation ( 2.1 ). Least square is the most 
common method to estimate the regression coefficients as it is equivalent to 
maximum likelihood estimation under the assumption of normally distributed error. 
Multivariate linear regression is an extension of simple linear regression having 
more than one independent variable. The relation between the dependant and 
independent variables is described in linear form as: 
                        ( 2.12 ) 
where    is a constant and    to    are the coefficients of   independent variables.  
Linear regression is limited to continuous dependant variables. This limitation 
prohibits its application in classification problems with dichotomous outputs such as 
medical studies with a binary output of the presence and absence of the disease. LR 
is the most common statistical technique utilised to overcome this limitation. 
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2.2.4. Logistic regression  
To overcome the limitation of linear regression in handling dichotomous 
classification problems, LR was proposed in early 1970s and become widely 
available to researchers through statistical software in early 1980s [34].  
In medical diagnosis, where the disease outcome is described as present or absent, 
the outcome is a binary variable taking values of   or   similar to the LR 
classification outcome. Hence, LR has been routinely applied and became a standard 
method in the field of medical diagnosis as a technique which is simple to apply 
through several statistical packages. In breast cancer, LR has been frequently used to 
predict dichotomous outcomes of patient survival, diagnosis and prognosis [35-38].  
As a linear multivariate analysis technique, LR describes the relation between one or 
more independent variables and a binary outcome. LR employs the same principles 
as linear regression for data analysis. Like linear regression, a model is developed to 
fit the input-output data by estimating a set of coefficients.  However, because the 
output can take any value from a continuous range of outcomes in linear regression, 
it is difficult to assign a dichotomous output to ( 2.2 ). For this reason, logistic 
distribution is used for describing the input-output relationship that is defined as the 
conditional mean of the output   given the input   [39]: 
            
       
         
 ( 2.13 ) 
Since the output is dichotomous (i.e.      ),      can be described as the 
probability of the output happening      . Similarly, the probability of the output 
not happening       is defined as       .  For final results, the output in (2.13) 
is transformed using a logit transformation. The logit transformation is the inverse of 
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logistic function and is defined as the natural logarithm (  ) of the odds of the 
output. The odds are the ratios of      to       . The LR output      is therefore 
defined as: 
        
    
      
         ( 2.14 ) 
Hence, instead of directly predicting the output from input variables, the logit of the 
output is predicted from the input. The equations ( 2.13 )  and ( 2.14 )  confirm that 
while the relation between the probability of the output,      and the input   is 
nonlinear; the relation between the logit of the output   and the input   is a linear 
one.  
Simple LR can be extended to multivariate LR by expanding the input x to a vector 
of multiple input factors X = {X1, X2, …, Xp}: 
     
                    
                      
 ( 2.15 ) 
The coefficients in LR are commonly estimated by maximum likelihood. In this 
method, the probability of the observed data as a function of the unknown 
coefficients is defined as a likelihood function. The unknown coefficients are chosen 
such that the likelihood function is maximised [39].  
LR regression outcome      retains some characteristics of linear regression such as 
linearity in parameters and continuity within the range of    to    depending on 
the range of  . Nevertheless, in LR conditional distribution of the outcome follows a 
binomial distribution [39]. One of the important properties that make LR the 
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desirable method of choice in medical studies is that it can be easily implemented 
and it also provides meaningful interpretation of the results. 
LR makes no assumptions about the underlying distribution of the independent 
variables. However, LR only models linear relationships between the dependant and 
independent variables. Besides, for a good estimate of the LR parameters, the 
independent variables should not be highly correlated. In addition, a fairly large 
sample size is required to supply sufficient data in each of the output classes for LR 
analysis. Sample sizes greater than 400 are suggested for each treatment group to 
build a reliable LR model [39].  
2.2.5. Discriminant Analysis 
The purpose of DA is to predict the class membership of a data point using a set of 
predictive variables. Simplest form of DA, linear discriminant analysis (LDA), was 
developed in 1936 by Fisher for data analysis and classification [40]. Similar to LR, 
LDA is suitable to be applied for linear classification problems with dichotomous 
outputs. For this reason, it can be a suitable method in medical diagnosis for 
identifying differences between patients with and without ALN metastasis and 
classifying them into one of these groups.  
LDA classifies data through maximising data separablility by projecting it into a new 
space where groups are maximally separated. Fisher LDA finds the transformation 
vector   such that the distances between the means of transformed inputs are 
maximised while the variances of the projected data in each group are minimised. 
24 
 
The means and variances of the original and the transformed data are defined as 
below: 
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( 2.19 ) 
where    and    are the means of transferred data in each group and    and    are 
their standard deviations (  shows that the values  are associated with the transferred 
data). In order to find a transformation vector   such that the distances between the 
means of transformed inputs are maximised while the variances of the projected data 
in each group are minimised, the function to be maximised for a two class problem is 
formulated as: 
     
       
 
  
    
  ( 2.20 ) 
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The obtained transformation vector   is then applied to the input vector   to 
transform it into a new space   . 
In order to obtain   from ( 2.20 ), the derivative of      with respect to   is 
computed. For this reason,      must be expressed in terms of   and the original 
data. Hence, the between-class and within-class scatter matrices,    and     are 
introduced as below:  
                 
  ( 2.21 ) 
         ( 2.22 ) 
And therefore, the numerator and denominator of ( 2.20 ) are presented as: 
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The transformation   is then obtained by solving the derivation of      with 
respect to  . Afterwards, a new datum can be classified by being transformed by   
and measuring the distance between the transformed datum and the mean of the 
transformed data in each group. The new datum is then assigned to the group which 
obtains the minimum distance. 
The main limitation of LDA in medical applications is that it only deals with 
continuous input variables and makes more assumptions about the input data 
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compared to other statistical methods such as LR. LDA assumptions about 
independent variables are multivariate normality and equal covariance. If these 
conditions are satisfied, LDA gives better or similar results compared to LR [41]. 
However, medical datasets are unlikely to lend themselves to these properties. 
Furthermore, it has been proved that LR performs better than or similar to LDA in 
most applications [41]. Therefore, the application of LDA in medical studies is 
limited.  
Some variations of DA have been proposed to obviate the limitations of LDA such 
as nonparametric LDA. In this method, the limitation of Gaussian assumption is 
removed by employing the k-nearest neighbours rule for computing the between-
class scatter matrix [42]. However, this method still has limitations when the 
between-class scatter matrix is singular.  
 
2.3. Problems with statistical methods   
Using more than one predictor is common in cancer studies as it is unlikely that one 
factor can provide discrimination between patients with and without a specific 
outcome. For this reason, multiple predictors are employed to classify the cancer 
outcome which gives rise to a multidimensional input space. The relationship 
between multiple predictors is typically a nonlinear and complex one which renders 
the linear statistical methods insufficient for these classification problems. In 
additions, many statistical methods make prior assumptions about the data such as 
multidimensional normality that is not generally true in cancer studies.  
An example of a nonlinear classification problem with two predictors (i.e. 2-
dimensional input space) and a binary output variable is shown in Figure 2.1 (a) and 
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(b). In these figures, problems with nonlinear decision boundary and closed curve 
boundary are presented [43]. In both cases, a linear classifier such as LR or LDA 
would fail to separate the data. In order to employ linear statistical methods for 
problems with nonlinear decision boundaries, data can be transformed nonlinearly 
into a new space where it is more separable and methods such as LR or LDA can be 
used. Then again, there is no guideline on how to choose an optimal nonlinear 
transformation and hence, it is unlikely to find a transformation that projects data 
into a space where it is completely separable. 
ANNs can solve this problem by automatically determining the data transformation 
and finding an optimal decision boundary. MLP is a specific ANN architecture 
which resembles a form of nonlinear DA that can overcome LDA limitations by 
transforming the inputs in a nonlinear fashion. Like DA methods, ANNs utilise 
training data with known outcome to build a model with which a new datum can be 
classified. However, they make no or little assumptions about the data and are able to 
learn nonlinear patterns from training data [44]. For this reason, they are chosen as a 
desirable classification technique in many real-world problems [45, 46]. In addition, 
ANNs yield higher accuracy in cancer diagnosis and prognosis compared to 
conventional statistical methods such as LR and Bayesian classifier [13, 14, 47, 48]. 
ANNs are the main platform used in this study and are fully discussed in the later 
sections of this chapter.  
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Figure 2.1: Nonlinear classification problem with two predictors and a binary 
output with (a) nonlinear decision boundary and (b) closed curve boundary. In 
both cases, linear classifiers fail to separate the data. 
 
2.4. Machine learning techniques in cancer 
diagnosis 
 
Machine learning is a branch of artificial intelligence that embraces a wide range of 
methods including DT, rule induction methods, Bayesian learning, genetic 
algorithms and ANNs [49]. These methods employ various statistical and 
optimisation techniques to provide decision making by learning complex patterns in 
a population from a sample set of data. Because of this characteristic, machine 
learning techniques have been widely applied in the field of medical diagnosis and 
prognosis.  
Machine learning methods generally achieve 15-20% improvement in accuracy for 
predicting cancer survival and recurrence besides providing more insight about the 
(a) (b) 
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nature of cancer progression. Among various machine learning techniques, DTs are 
among the most widely used methods in cancer diagnosis [50]. DTs are successfully 
applied to ovarian and gastric cancers [51, 52]. However, DTs are usually used in 
conjunction with another classification method to achieve better classification results 
[53, 54]. A brief history of DT in medical literature, its structure and learning 
algorithm, in addition to its advantages and disadvantages are explained in the 
following section.  
2.4.1. Decision tree (DT) 
DT learning is an inductive inference algorithm that can approximate discrete 
outcomes using a set of training data. The learned function by DT is represented by a 
set of branches and nodes that are structured as a graph. The graph starts from a root 
node that is attributed to one of the input variables followed by leaf nodes attributed 
to each of the remaining input variables. The outcome of the tree is a category into 
which the input is classified. An example of the structure of a DT for a simple 
classification problem is presented in Figure 2.2 [49]. In this example, the aim is to 
decide whether to play tennis or not. The decision depends upon the weather forecast 
and is   if: 
Outlook = Overcast 
OR  Outlook = Sunny AND Humidity = High 
OR  Outlook = Rain AND Wind = Weak  
The output would be otherwise 0.  
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Figure 2.2: A decision tree structure to decide whether to play tennis or not 
based on weather forecast. The output is either 1 for play tennis or 0 for not 
play tennis. 
 
The simplest form of learning in DT consists of a greedy search that starts from the 
root node and only goes down without backtracking to the previous nodes [49]. The 
root node is selected using a predefined measure. The training data are then assigned 
to the succeeding leaf nodes based on their values of the root node variable. The leaf 
nodes’ variables are then selected using the same measure and a similar process is 
repeated until a decision is reached or no further division is possible. In ID3 decision 
trees, the measure for choosing the best attribute in each step is information gain 
[55]. This measure quantifies how well each variable classifies training data into 
output categories. Information gain is defined using a well known measure in 
information theory called entropy. The entropy of the dataset   in respect to a two 
category output class is defined as:  
Outlook 
Humidity  Wind 
Sunny  Overcast  Rain  
1  
High   Normal  Strong  Weak  
0  1  1  0  
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 ( 2.26 ) 
where     is the proportion of the data points in   belonging to class  . Entropy can 
take values between 0 to 1 depending on the proportion of each class in the data. If 
all the data belongs only to one category, the entropy is equal to   while it is   when 
there are equal numbers of each category. An unequal number of output categories 
result in an entropy value between   to  . The information gain of a variable is then 
defined as: 
                    
    
   
           
            ( 2.27 ) 
where   is the input variable and           are its possible values.    is the subset 
of   for which variable   has values  .  
DTs maintain several advantages that have made them attractive in medical 
diagnosis. The results provided by DTs are easy to interpret in terms of if-then rules.  
In addition, DTs are considered as robust classifiers with quick learning [49]. 
However, DTs do not perform as well as ANNs in complex classification problems 
[56]. 
One limitation in DTs is that each attribute is required to have a small number of 
discrete values. To address this problem, continuous variables are partitioned into 
discrete intervals. A new dummy variable is then introduced that takes discrete 
values attributed to each of the intervals. The main disadvantage of implementing 
continuous inputs in DT is the loss of information that occurs due to partitioning. 
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Another problem that arises with partitioning the continuous variables is selecting 
the appropriate intervals.  
Furthermore, DTs are highly prone to overfitting. DTs may present good predictions 
for small training data with missing values. In effect, a large tree may separate the 
training data perfectly with no misclassification error. However, such model may 
overfit the data by having few training samples at the end of each branch which 
means low generalisation ability for new data.  
Support vector machines (SVMs) are another machine learning technique which can 
be classified as Kernel-based methods [55]. SVMs are supervised learning methods 
based on the statistical learning theory and the Vapnik-Chervonenkis dimension 
[56]. For a linear classification problem with dichotomous outcomes, SVM finds the 
decision boundary in the form of a hyperplane such that it is as far as possible from 
the closest members of both classes. In nonlinear SVMs, the data are recast into a 
higher dimensional space by using a nonlinear kernel function such that they are 
linearly separable in the new space. It has been shown that SVM performs as good as 
ANNs such as the PNN in breast cancer detection [57]. However, using a nonlinear 
SVM means that an appropriate kernel function and its parameters should be chosen 
such that the nonlinearly separable data can be mapped into a higher dimensional 
space where it is linearly separable. Unfortunately, there are no specific rules for 
choosing such function and it is commonly chosen using trial and error from a set of 
predefined kernel functions. This makes the success of SVMs dependant on finding 
an appropriate transfer function which might not be possible for highly nonlinear and 
complex data. 
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2.5. Neural Network Models  
DSSs for cancer diagnosis have been widely employed in clinical practice. A 
considerable number of these systems involve ANNs. A wider context of DSSs in 
medical diagnosis and other methods routinely employed in cancer diagnosis 
including statistical and machine learning methods have been already covered in the 
previous sections. In this section, a specific review of ANNs and their application in 
cancer diagnosis is detailed. 
ANNs’ basic form and the preceptron concept were first introduced by McCulloch 
and Pitts in early 1940s as a tool for simulating the human intelligence [57]. ANNs 
exploit special characteristics of human brain such as reasoning, making decision 
and learning by experience. ANNs are proved as valuable classification tools in 
many applications such as business, science and engineering [46]. They maintain 
several advantages over conventional statistical methods especially for data that 
exhibits nonlinearity. The vast amount of research conducted in this field has 
established that ANNs perform better than various statistical, machine learning and 
rule-based methods such as LR, DA and DT [58-60].  This is due to the special 
theoretical properties of ANNs including: 
- ANNs are nonlinear models. Hence, they are suitable for real world 
applications and especially cancer prognosis in which there exists a 
nonlinear and complex relationship between the biomarkers and 
cancer outcome. This nonlinear modelling is established in the 
following sections where the theoretical principles of ANNs are 
explained. 
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- ANNs can be trained to learn data patterns by means of adaptable 
weights. This makes them suitable for data driven analysis without 
making any prior assumptions about the underlying models. 
Because of these advantages, ANN systems have been employed as medical DSSs 
from the time when early computing systems where introduced [31]. Since then, 
there has been wide research and many improvements on the application of ANN in 
medical diagnosis. However, it has been only in the past two decades that ANNs 
have been practically applied in the field of medical decision making [36]. This has 
helped many physicians in making medical decisions more confidently and in a 
timely fashion.  
2.5.1. An overview of artificial neural networks 
ANNs are a branch of artificial intelligence that are able to learn complicated 
nonlinear patterns from a set of data. ANNs are parallel computational units which 
have become a valuable classification tool in recent years. They first originated from 
the idea of simulating human brain abilities in decision making and parallel 
processing by combining mathematical modelling and engineering design. While the 
basic structure and characteristics of ANNs still resemble the human brain, their 
functioning and the way they make decisions have become far different from 
biological neural networks over time.  
Different types of ANNs can be categorized by two main criteria [61]. First criterion 
is how the network is encoded, i.e. how the network stores knowledge from the data. 
Using this measure, ANNs are categorised as supervised and unsupervised. Second 
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criterion is the way the networks are decoded, i.e. the way the network processes 
new data once it has acquired knowledge from the old data. This criterion classifies 
ANNs into feedforward and feedback. Figure 2.3 illustrates this classification.  
In a supervised network, both the input and output are presented to the network. The 
network weights are then adjusted by computing an error from comparing the 
network output and the desired output. The optimum weights are obtained by 
optimising the error function. Afterwards, the ability of the network in classifying 
new data is tested by presenting new inputs to the network and comparing the answer 
with the unseen output. Some ANNs have the ability to learn without teachers. The 
learning process when only inputs are presented to the network is termed as 
unsupervised learning. This is achieved by using rules for self-adjustment as the new 
inputs are presented to the network. The self-adjustment is performed based on 
predefined rules [62].   
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Figure 2.3: Different types of ANNs can be categorized by two main criteria: 
how they are encoded, (supervised and unsupervised) and how they are decoded 
(feedforward and feedback).  
 
Excessive and continuously growing literature is available on ANNs [46, 62-65]. 
The theory of ANNs is derived from different disciplines including mathematics, 
statistics, biology, engineering, computer science and neuroscience. Each of these 
disciplines contributes to the capability of ANNs as intelligent systems to be 
employed in a wide range of applications. A comprehensive explanation of the 
mentioned disciplines forming the foundations of ANNs is out of the scope of this 
thesis. Therefore, the focus is only on the paradigms that contribute to the ANNs 
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applied in the field of medical diagnosis and more specifically, to breast cancer 
prediction. In the following sections, the fundamentals of the ANNs are briefly 
explained to prepare the grounds for further explicating the ANN models used in this 
project.  
 
2.5.2. Neurons 
As mentioned above, the structure and function of ANNs resemble the human brain, 
in that they include a massively parallel architecture, but in a relatively small scale. 
Whilst human brain is made up of 10
11
 neurons in average, ANN is based on layers 
of computing nodes which include only a few computing units. 
Biological NNs consist of controlling units called neurons which have the ability to 
learn and work in parallel. ANNs emerged in 1943 for the first time by representing 
a simple form of biological neurons by elements that could perform computation 
[57]. 
Biological neurons have different specialisation and functioning. A simplified 
structure of a Biological neuron consists of four main parts. Each neuron has a cell 
body called soma which can receive input from nearly 10000 other units through an 
assembly of subtle structures called dendrites. After processing the received signal, 
the neuron sends out an electrical potential through a long, thin structure called axon 
which divides into many branches. Afterwards, the electrical output is transferred to 
the dendrites of other neurons via junctions called synapse. This structure is 
illustrated in Figure 2.4. 
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Figure 2.4: A biological neuron 
 
For creating an ANN model based on a biological NN, there are three important 
components of a neuron to simulate. The synapses are represented as weights which 
define the strengths of the connection between nodes. The dendrites and axon are 
modelled as the actual activity taking place in ANN nodes where all the inputs are 
summed up by considering their weight through a process called linear combination. 
Finally, the output amplitude of the neuron is defined by an activation function.  
An artificial neuron can be considered as a simplified biological neuron in that it has 
the ability to learn from previous data and predict the output for new data. However, 
the processing rate, size, complexity level and the fault tolerance of them is not 
comparable. A simplified model of an artificial neuron is illustrated in Figure 2.5 in 
which n inputs denoted by Xi are weighted through wi weights and summed up by Σ, 
then passed through an activation function indicated by φ and transferred to the 
neuron output expressed by O. An artificial neuron also contains bias which is an 
external input for adjusting the net input of the activation function. Bias can be 
Dendrites 
Cell body 
(soma) 
Axon 
Synaptic gap 
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considered as the 0
th
 input weighted by a unit connection. Hence, the output of a 
neuron can be formulated as: 
      
 
   
    ( 2.28 ) 
Where the sum of the weighted inputs (   
 
     ) is called the activation of the 
neuron.       
 
 
Figure 2.5: A simplified model of an artificial neuron 
 
Activation function defines the output level of the neuron for a given input. There 
are three general types of activation functions namely identity, threshold and sigmoid 
transfer functions. When the net input weights to the neuron are transferred to the 
output directly, without any changes, the neuron is considered to have an identity or 
linear transfer function. A linear activation function can be simply formulated as: 
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       ( 2.29 ) 
with   being the activation of a neuron. In threshold activation functions, the output 
takes the value of    if the input is larger than a defined threshold t and takes the 
value of 0 otherwise: 
      
                
                
  ( 2.30 ) 
Some activation functions such as logistic or hyperbolic tangent are considered as 
sigmoid transfer functions. These functions have bounded range in the output; hence, 
they are also referred as ‘squashing’ functions. Logistic function is defined by:     
                    
 
          
 ( 2.31 ) 
where s is the steepness parameter defining the slope of the function and b is the bias 
of the function defining its location on the horizontal axis.  
Similarly, a hyperbolic tangent function is defined by: 
                  
          
          
 ( 2.32 ) 
These transfer functions are illustrated in Figure 2.6.  
 
41 
 
  
Figure 2.6: Linear, threshold, logistic and hyperbolic tangent transfer functions  
 
Sigmoid transfer functions are commonly used in ANNs because of their special 
mathematical properties. These properties include continuity, differentiability at all 
points and monotonicity (i.e. monotonically increasing in a finite range).  Among 
Sigmoid functions, hyperbolic tangent is preferred over logistic function because of 
its symmetrical output.     
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2.5.3. Rosenblatt’s perceptron 
The first model for supervised learning called perceptron was introduced by 
Rosenblatt in 1958 [66]. Rosenblatt’s perceptron is still valid as the simplest form of 
an ANN for classifying linearly separable patterns (i.e. patterns that can be divided 
into two distinct classes via a hyperplane).  
Perceptron consists of a single neuron with adaptable weights and bias. Training in 
perceptron is inspired by biological neural systems. This is accomplished by 
reinforcing good behaviour (correct output) and discouraging bad behaviour 
(incorrect output). In perceptron, reinforcing and discouraging is simulated by 
adapting weights of the connections linking the inputs to the neuron. The amount of 
weight change is decided by considering the distinction between the network and 
desired outputs. 
In order to measure the degree of closeness of the network output and the desired 
output, network’s error at step s is computed by subtracting the network’s output o 
from the desired output t: 
               ( 2.33 ) 
The weights are then updated as follow: 
                         ( 2.34 ) 
In the above equation,   is called the learning rate which has the effect of controlling 
the rate of change in the weights. This means taking smaller steps when the trained 
network is close to the desired solution and taking larger steps otherwise.   
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The process of weight adaptation is started by initialising the network weights 
randomly to a small value. The network output is computed accordingly and error is 
computed from ( 2.33 ). Then the weights are updated from ( 2.34 ) and the same 
process is repeated for several steps where the error is expected to reduce after each 
step. 
Rosenblatt proved that given two linearly separable classes, the perceptron algorithm 
converges to a hyperplane separating the input patterns into two distinct groups in a 
finite number of steps. This is known as the perceptron convergence theorem. A 
detailed proof of perceptron convergence theorem can be found in Haykin [62]. 
The perceptron algorithm is found to be insufficient in some aspects. One issue is the 
myriad number of solutions existing for a single linear problem depending on the 
initial weights. The second issue is that the number of steps needed to reach the 
optimal solution can be very large. Finally, when the problem at hand in nonlinear, 
the algorithm does not converge and remains in an indefinite loop of steps. To 
overcome these limitations, MLPs are introduced and structured as fully connected 
layers composed of perceptrons.  
Another type of feed-forward ANNs are radial basis function (RBFs). RBF neural 
networks are the main alternative to the MLP for nonlinear classification. A special 
design of the RBF for dichotomous outputs, called PNN, is devised as the main 
platform employed in this study. The MLP and the PNN, their structure, learning 
algorithm, advantages and disadvantages are detailed in chapter 4. These ANNs 
constitute the main approaches in this thesis and therefore, a history of their 
application in cancer prediction and diagnosis is entailed in the next section.  
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2.6. Neural network models for breast cancer 
prediction 
There has been significant number of publications on ANN approaches applied as 
DSS in cancer diagnosis and prognosis in the last two decades. An introduction to 
ANN applications in oncology and the impact of ANNs on cancer research can be 
found in [67]. A Lancet series published in 1995 covered the principles of ANNs and 
their application in classifying clinical data [32, 43, 68]. Numerous studies have 
confirmed the efficiency and reliability of ANNs in cancer prognosis [69]. Burke et. 
al. [15] has employed a MLP trained with BP and compared it to the conventional 
cancer prognosis method for 5-year survival prediction and has demonstrated the 
significant superiority of ANN.  
In a comparison between regression models and ANNs applied to classifying 
medical data, it has been suggested that with small datasets (less than 2000), ANNs 
outperform regression models [59]. In another comparison study, Burke et al. [14] 
advocate the superiority of ANN to linear and logistic regression and demonstrate 
that the performance of the MLP and the PNN in cancer prognosis are almost 
identical. Main reason for the better performance of ANN in the mentioned studies is 
the nonlinear and complex nature of input-output relation in cancer datasets. Hence, 
the classification analysis in cancer prediction is a nonlinear one which necessitates 
having efficient nonlinear classifiers. This is the primary reason for using ANN as 
the main predictive model in this study instead of conventional statistical tools. 
For the specific application of ANNs in prediction of ALN metastasis in breast 
cancer, a comprehensive review has been conducted by Patani et al. [7]. They have 
surveyed the studies investigating the prediction potential of biomarkers for 
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determining the ALN status. This review only entails those articles meeting five 
criteria including a clarified and complete explanation of tumour characteristics, 
study design, methods, results and the test significance (with P-value<0.05). 
Considering these criteria, only 30 articles out of 290 were included in the review 
which reveals the large number of unapproved studies in this field. Among these 30 
articles, only two were conducted using ANN. Both publications had employed MLP 
neural network for the analysis of a set of biomarkers to predict the ALN status [70, 
71]. It has been concluded that ANN based analysis of multiple biomarkers is 
advantages over conventional analysis techniques such as LR [7]. Other studies have 
also confirmed the capability of ANNs in providing accurate and reliable prediction 
for ALN metastasis status utilising tumour biomarkers [72]. 
Among various ANN architectures, MLP has been the most widely used method so 
far for cancer prediction and prognosis [20-22]. The effectiveness of MLPs in breast 
cancer diagnosis has been evaluated using clinical, pathological and 
immunohistochemical data which suggest MLP as a powerful technique for cancer 
prediction [73]. Nevertheless, MLPs suffer from some common drawbacks including 
network’s complexity, numerous network variables required to be optimised and 
random weight initialisation.  
Another ANN architecture that has been found suitable for numerous applications in 
recent years is the PNN. The PNN, first introduced by Specht in 1988 and 1990, is 
capable of defining decision boundaries exploiting Bayesian theory [23, 24]. This 
quality makes the PNN an effective technique for classification and pattern 
recognition tasks, especially when used for datasets containing samples adequately 
correlated to the associated class and well separated categories [25]. The PNN also 
trains faster than the MLP and requires fewer variables to be optimised. Although 
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this method has been known for quite a while, it has only recently been identified as 
an effective classifier for cancer diagnosis and prediction [26, 27].  
2.6.1. Advantages  
The basic requirement of supervised ANNs for data classification is a large enough 
dataset with known inputs and outputs for training and test. In this, ANNs are similar 
to any other statistical or machine learning algorithms employed as a DSS. ANNs 
owe their extensive application in cancer prediction to several special characteristics 
in their theory and structure. These include ANNs’ nonlinear modelling and 
maintaining adaptable connection weights which makes them suitable for data driven 
analysis without making any prior assumptions about the underlying models.  
ANNs can achieve good results with fewer data compared to data sizes estimated by 
statistical sample size computational methods [43]. It is because the ANNs are 
efficient in using the available data by extracting higher-order statistics. This also 
gives flexibility to ANNs in achieving significant results in a wide variety of 
applications and especially in medical diagnosis [68]. 
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2.7. Neural network performance evaluation 
One of the important issues in ANN classification is whether the approximated 
classification rule based on limited sets of data can represent a whole population of 
patients. Therefore, the designed ANNs need to be assessed with new data which is 
not used for constructing the classification rule in the training procedure. 
In recent years, many prognostic models have been developed to perform the task of 
medical diagnosis and classification using ANNs. An extensive consideration has 
been given to the stage of classifier design for developing the prognostic model. 
Conversely, the stage of the classifier assessment given the limited available dataset 
has been overlooked by many studies. This issue was raised in 1995 and the 
importance of validating prognostic models in order to ensure the effectiveness of 
the models was highlighted [74]. 
To assess the ability of the network in predicting the outcome, the network predictive 
performance for new patients should be evaluated. For this purpose, the available 
data are divided into two parts: the training and the test sets. The designed network is 
trained using a training set of data. The training set X contains the markers and the 
known output, both of which are used to facilitate the learning process via supervised 
learning.  The test set is kept unseen and used only after training is complete to 
estimate the performance of the ANN.  The implemented ANN must provide a set of 
classifications for the records in the test set which are then being compared with the 
known output to deduce the accuracy of the system.  For a dichotomous target   , the 
network provides dichotomous outputs    and hence, the output error Ei would take 
only two values as 
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  ( 2.35 ) 
An ideal error estimation method is the one with zero bias and variance. However, 
achieving such estimation is unfeasible in practice as the dataset is only a small 
sample of the population and hence a trade off between the bias and variance of the 
error estimation technique is sought.  
2.7.1. Estimation of classification error  
ANNs classify new patterns by constructing prediction rules from a training dataset. 
After training the ANN with teacher, it is necessary to measure the accuracy of the 
designed network. The simplest measure for the network accuracy is the training 
error also denoted as apparent error   in some texts. This is performed by testing the 
classifier with the same data employed for training and is defined as the ratio of the 
misclassified samples to the total number of samples when the training is stopped: 
   
 
 
          
 
 
   
 
   
 
   
 ( 2.36 ) 
This measure is not a true presentation of the classification accuracy. This is because 
the prediction rules are constructed using the same training patterns and hence 
provide an error estimation that is significantly biased downward (i.e. 
overoptimistic). Therefore, the error rate obtained by testing the network with the 
same training set is not a reliable measure of the network’s error rate for new 
49 
 
patterns.  This is a well known fact and medical studies using ANN for diagnosis do 
not exploit training error as a measure of classification error [20]. 
In order to reduce this bias, holdout method is carried out by random division of data 
into training and test sets where the classifier is designed using merely the training 
data and hence the test data are kept unseen. Holdout method is commonly used in 
experiments carried out with ANNs. However, it is not an efficient method in small 
datasets since a part of data are held for test and it cannot be used for the network 
training. Holdout method would also give a high variance in the estimated error rate 
depending on the random selection of training and test data. 
Another method preferred over holdout is k-fold CV. In this method, data is divided 
into k groups. Then, the network is trained with k-1 groups keeping one group as the 
test set. This procedure is repeated for k times until each group is used once for test. 
Final prediction accuracy is then computed as the average of k test results. Hence, all 
data are used for training the network at least once and the test set is kept unseen to 
the network. Furthermore, CV is known to provide an unbiased estimate of error 
rate. However, this low bias comes at the cost of high variability especially for 
discontinuous outputs for which k-fold CV error estimate function is a discontinuous 
function of training set [75].  
Bootstrap technique is an alternative method for CV which reduces the variability in 
error estimate by using data resampling technique and maintains a low bias in 
estimating the misclassification error [76]. This method is detailed in chapter 4 as the 
main technique employed to evaluate the designed ANNs in this study. 
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2.8. Summary  
In this chapter, a review of the foundation of medical DSSs has been explained. 
Then, a brief history and principles of the most widely employed statistical and 
machine learning methods for breast cancer prediction including LR, DA and DT 
was included. The discussion on the advantages and disadvantages of these methods 
has demonstrated the ineffectiveness of these methods in medical diagnosis. 
Regression models are the most commonly used statistical method in medical studies 
which make no assumptions about the underlying distribution of the independent 
variables. However, they have several drawbacks including their limitation to linear 
modelling and their requirement for independent variables and a large sample size. 
The disadvantages of LDA that hinders its widespread application in medical studies 
include its limitation to continuous input variables and input data assumptions such 
as multivariate normality and equal covariance for independent variables. Among 
various machine learning techniques, DTs are the most widely used methods in 
cancer diagnosis. However, they are prone to overfitting and are limited to variables 
with small number of discrete values. In general, the relationship between multiple 
predictors is typically a nonlinear and complex one which renders the linear 
statistical methods insufficient for these classification problems.  
The sections on the statistical and machine learning methods have led to the 
conclusion that a more effective classifier is required for capturing the nonlinearity 
in the medical data. ANNs were then introduced as valuable classification tools that 
maintain several advantages over conventional statistical methods especially for data 
that exhibits nonlinearity. This chapter has also covered the principles of ANNs and 
their history in medical diagnosis. In addition, the necessity for reliable error 
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estimation and the currently employed methods were detailed in this chapter. The 
main ANN architecture and evaluation method employed in this study are explained 
in chapter 4. 
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Chapter 3 
3. Minimally invasive biomarkers 
for breast cancer prediction 
3.1. Introduction  
In recent year, many studies have focused on devising an approach to avoid the 
invasive procedures for predicting breast cancer. Various tumour biomarkers have 
been discovered and tested in this regard to enable physicians to predict breast 
cancer before performing invasive treatments. However, individual tumour markers 
alone are not a good predictor of breast cancer progression as a combination of 
various biomarkers can give a better prediction of nodal status in individual patients.  
In this chapter, a novel set of biomarkers is proposed for the purpose of predicting 
the progression of breast carcinoma. While these markers have been known in the 
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literature of breast cancer prediction, their combination together forms a novel 
relation with the output of breast cancer progression considered in this study.  
The first section of this chapter, introduces the measure employed for quantifying 
breast cancer progression. The biomarkers chosen in this study are then listed and the 
dataset characteristics, in addition, to the biomarkers’ measurement methods and 
descriptive statistics are explained. The third part of the chapter entails a medical 
literature of the chosen biomarkers to establish their individual roles and application 
in predicting breast cancer progression. In the final section, the scatter plots of the 
markers with regards to the breast cancer output are illustrated and their correlation 
coefficients are presented. This section aims to investigate the relationship between 
different markers and the output visually and quantitatively.  
 
3.2. Breast cancer prediction using axillary 
lymph node metastasis 
Deciding the state of tumour spread to the ALNs is the most influential prognostic 
factor in women diagnosed with breast cancer [77]. The status of ALN involvement 
is an important factor in making the appropriate decision about treatment type and 
timing for patients with breast carcinoma.  The invasion of cancer to the ALNs is 
typically determined by excision of ALNs and histological detection of tumour cells 
in the specimens, or by SLNB. ALN dissection and SLNB are invasive procedures 
and may cause pain, bleeding and infection. Besides, they are costly and patients 
diagnosed with no invasion to the ALNs after node dissection and the SLNB are 
imposed with unnecessary morbidity. Therefore, it is important to devise minimally 
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invasive surrogate methods to determine the potential presence of any metastasis to 
the ALNs prior to surgery. 
In recent years, much attention has been focused on the prediction of ALNs using 
various tumour markers such as clinical, pathological and radiological features. 
Patani et al. [7] identified these markers as predictive and non-prognostic, since 
predictive factors are employed for predicting metastasis to the ALNs, whilst 
prognostic markers are employed for predicting clinical outcome such as overall 
survival.  There is little agreement to date on single or a combination of biomarkers 
for accurate nodal status prediction that can replace the conventional techniques such 
as axillary dissection or SLNB. Single tumour biomarkers alone do not predict the 
potential progression of breast cancer to ALNs. A combination of various 
biomarkers can give a better prediction of nodal status in individual patients.   
 
3.3. Breast cancer dataset 
In an attempt to find minimally invasive surrogate techniques for predicting the 
spread of breast cancer to the ALNs, this study has identified several molecular and 
cellular markers that dominate the field of tumour progression. These can be classed 
as: (a) cell cycle regulatory genes and cell proliferation markers, (b) metastasis 
promoter and suppressor genes, (c) hormonal and growth factor receptors, and (d) 
biological features. The expression of molecular markers is measured in tumour 
tissue using immunohistochemistry (IHC)
2
 to quantify the protein. These parameters 
                                                 
2
 IHC is the procedure of detecting antigens in cells based on the binding of 
antibodies to particular antigens in biological tissues. 
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are routinely measured on fine needle aspirate (FNA) cells derived from the primary 
tumour.  
The dataset employed in this study was collected in the Department of Clinical 
Oncology and Department of Anatomy, Pathology and Histology, Infermi Hospital, 
Rimini, Italy. The data consist of records of 108 patients from which 47 patients 
were diagnosed with metastasis in ALNs (node positive) and 61 did not show any 
metastasis (node negative). The data include information about the five tumour 
markers viz. tumour size, ER, PR, p53 and Ki-67, in addition to the age of each 
patient at the time of diagnosis (aged 27 to 83 years old). 
 
3.3.1. Measurements and descriptive statistics  
Tumour size was determined by measuring the largest dimensions of the tumour 
from mammograms
3
 and was expressed in centimetres as a continuous variable with 
a range of 0.5 to 5.5 centimetres. ER and PR levels were simply expressed as present 
(1) or not present (-1). (1) was denoted when the receptors were detected by IHC in 
more than 10% of cells or when receptor level was greater than 20 fmol/mg protein 
while (-1), when receptor levels were below 20 fmol/mg protein
4
.  The expression of 
p53 and Ki-67 was given as a percentage of cells stained positive in IHC tests and 
was stated as continuous variables. The presence of nodal metastases was also 
available for each patient and has been considered as the system output.  Nodal data 
                                                 
3
 Because the tumour does not have a regular shape, the greatest dimension is used as a 
indication of size. 
 
4
 fmol/mg protein is a a way referring to the amount of ER or PR receptor protein in one mg 
of total cell protein; fmol is an abbreviation for femtomole which is 10 to the power of -15 
of a mole (i.e. a billionth of a mole). Hence, receptor level of fmol/mg protein refers to 
femtomole of receptor /gram of cell protein. 
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were originally provided as the number of positive nodes over the total number of 
nodes tested. To employ nodal status as ANN output, node negative patients were 
designated as (-1) and patients with even one positive node were designated as (1). 
Markers considered in this study and their descriptive statistics are tabulated in Table 
3.1 and Table 3.2 for continuous and binary markers respectively. A description and 
history of these biomarkers in clinical domain is provided in the following sections. 
 
Table 3.1: Continuous tumour markers and their descriptive statistics 
Tumour marker Minimum Maximum Range Mean Std. deviation 
Tumour Size (cm) 0.50 5.50 5.00 2.07 0.92 
p53 (%) 0.00 0.90 0.90 0.16 0.26 
Ki-67 (%) 0.03 0.80 0.77 0.31 0.16 
Age (years) 27 83 56 58.12 12.88 
 
Table 3.2: Binary tumour markers and their descriptive statistics 
Tumour marker Frequency of 1 Frequency of -1 
ER (Oestrogen Receptor Status) 69% 31% 
PR (Progesterone Receptor Status) 56% 44% 
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3.4. Biomarker descriptions  
3.4.1. Tumour size  
Tumour size has been identified as a significant prognostic marker both 
independently and in combination with other markers for ALN prediction [78]. 
Progressive tumour growth increases the likelihood of vascular and lymphatic 
dissemination and so the size of the tumour is directly related to higher chances of 
local metastasis, recurrence and death. It also has an influence on the prognosis of 
both node-positive and node-negative cases, where increased tumour size has been 
associated with decreased survival regardless of lymph node status [79]. However, 
this effect is greater in node-positive than node-negative patients as reported by 
Carter et al. [80]; whereas, no relation between tumour size and survival was 
observed in node-negative patients by Vallagussa et al. [81]. Nevertheless, size of 
the tumour is considered as one of the most significant predictors of tumour 
behaviour. It has been reported that patients with small tumours (less than or equal to 
1.0 cm) have significantly higher rates of relapse-free survival than those with larger 
tumours, with 96% remaining relapse free at 5 years.  
 
3.4.2. Oestrogen and progesterone receptor status  
The female steroid hormones, oestrogen and progesterone, stimulate the growth of a 
variety of target tissues via binding to their respective receptors (ER and PR), which 
promotes tumor growth. The hormone-receptor complex functions as a transcription 
factor and initiate the transcription of responsive genes resulting in appropriate 
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physiological function. Oestrogen and progesterone are known to influence the 
function of different homeobox transcription factors in breast cancer cells. Therefore, 
they could be inducing the transcription of specific target genes associated with cell 
proliferation and differentiation. 
The presence of steroid hormone receptors subserves an important function as 
effective therapeutic targets. Breast cancers that express oestrogen and progesterone 
receptors are targeted by using anti-oestrogens. Hence, the absence of ER in breast 
cancer is regarded as an indicator of poor prognosis, since ER- tumours would be 
resistant to anti-oestrogen therapy, and can continue to grow rapidly and result in 
poor patient outcome. Hypermethylation and down-regulation of ER gene expression 
also occurs in many human tumours. In some cases, the silencing of the ER gene 
correlates with disease progression. ER and PR expression status is significant in 
determining response to endocrine therapy. Patients expressing both receptors have 
the best prognosis and are more likely to respond to hormone treatment than patients 
with ER+/PR- tumours [82]. PR+ patients however, appear to respond better to 
hormonal therapies with a higher survival rate consequently [83].  
In breast carcinoma, the PR gene is also down regulated. PR seems to be the main 
component of ER functional pathway and ER could be regulating PR. In some 
instances, ER+ breast cancers have been found to be refractory to anti-oestrogen 
therapy. ER are known to be able to induce the expression of PR, and often a 
reduced response to hormones is perceived as a non-functional state of ER [84]. 
Hence, PR has been recognized as a prognostic factor independent of ER. In 
employing these markers for assessing tumour progression, one should note the 
interaction between the signal transduction pathways of these steroids. In breast 
cancer cells, both oestrogens and progesterone can activate a common signalling 
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pathway viz. the Src/Erk pathway. Ballaré et al. [85] have attributed this to the two 
domains of PR which interact with ER. On the other hand, progesterone can 
negatively regulate other oestrogen regulated signalling pathways leading to 
inhibition of proliferation [86]. In other words, cross talk between steroid receptors is 
bound to impinge upon progression of the disease. 
 
 
3.4.3. p53 
Only around 20% of all human breast cancers have a p53 mutation [87], but specific 
types of breast carcinomas such as medullary breast cancers have higher p53 
mutation frequency (100%) [88]. Mutations in the p53 gene or inactivation of its 
protein has been shown to play a role in several types of cancers [89].  p53 functions 
as a cell cycle regulator. In cells with damaged DNA, there is an over expression of 
p53 and cells are prevented from entering the synthetic phase until the DNA damage 
is repaired. p53 may also trigger a cell suicide response in cases where DNA is 
irreparable.  Where p53 is mutated or lost, the cells continue to divide and replicate 
the damaged DNA, passing on mutations to daughter cells. p53 is known to prevent 
the formation of tumours by preventing progression of the cell cycle, in particular 
G1-S and G2-M transitions.  Therefore, p53 is considered as a good guide for the 
prediction of breast cancer patient survival.  Nevertheless, there is little evidence that 
p53 can be used as an indicator of initial tumour formation [90].  The perceived role 
of p53 in cell cycle regulation is not often considered significant, as most studies 
recognize that there is a poor correlation between p53 and metastasis in breast 
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cancer.  As an instance, Erdem et al. [91] suggested that p53 offers no significant 
prognostic value.  
Studies have shown that breast cancer patients with a mutant p53 respond differently 
to those with wild-type by being resistant to certain chemotherapy regimens while 
sensitive to others [92]. However, it is still not possible to conclude how p53 
mutations can impact breast cancer therapies and patient’s overall clinical outcome 
which in turn highlights how several other factors might be influencing the p53 
network [93].  
3.4.4. Ki-67  
The Ki-67 protein is a growth promoter antigen, present in all but the resting G0 
cells. The Ki-67 antigen is expressed on the outer surface of the nucleolus, especially 
in its granular component during late G1, G2 and M phases of the cell cycle. So the 
determination of its expression serves as an accurate cell proliferation index and 
hence employed in a diagnostic and prognostic role [94]. It has been shown that 
evaluation of Ki-67 antigen can serve as the proliferative determinant of early breast 
cancer as reviewed by Azambuja et al. [95].  Even though, Ki-67 labelling index 
which is a percentage of Ki-67 antigens detected using nuclear immunoassays is 
determined by histopathologists, it cannot be used as an accurate clinical prognostic 
marker for breast cancer. Ki-67 labelling index can vary from one histopathologist to 
another depending on the site of tumour selection for counting, cut-off levels, as well 
as the detection kits or antibody used for the immunoassays [96].  
In a recent study, it has been demonstrated that a combination of biomarkers which 
comprises of both Ki-67 and p53 are able to better predict the outcome of early ER+ 
breast cancer patients [97]. Thus, the wide spectrum of molecular markers has 
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afforded an excellent opportunity to relate their expression as an integrated body of 
biological response modifiers to breast cancer progression. However, their apparent 
complex interaction has necessitated the development, evolution and validation of 
artificial intelligence techniques such as ANN. These techniques offer the possibility 
of assessing various markers and their biological effects for their ability to predict 
the cancer progression so that appropriate treatments can be tailored to combat the 
disease. 
3.4.5. Age  
As a very basic part of the patient dataset, age is still included in most analyses of 
breast cancer. However, the relationship is not necessarily that simple because 
aggressive tumours may form early in life cycle. But, age is commonly used in 
deciding treatment levels as it can be considered as an indicator of the resilience of 
the patient to aggressive treatments. 
Early breast cancer incidents are increasing in young women. It has been frequently 
reported that women who are younger than 35-years old have a poorer prognosis 
than women older than 65-years old. Patients less than 35 years of age have 
significantly shorter survival time which is also true in the presence of other good 
prognostic factors and regardless of their menopausal status. The underlying reason 
however, remains unclear. Younger women diagnosed with breast cancer are more 
likely to have ALN metastasis, higher frequency of undifferentiated tumours, with 
high histopathological grading while also negative for ER. In addition, younger 
patients have a higher risk of local recurrence and developing distant metastases. In 
recurrent breast cancer, one study predicted the median survival times after the first 
recurrence to be 491 days for patients less than 35 years of age, 590 days for patients 
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36 to 45 years of age, and 700 days for those greater than 45 years of age [98]. 
Moreover, metastasis-free survival and overall survival are also significantly shorter 
in younger age groups. All this indicates that breast cancer is biologically more 
aggressive among younger women compared to older women and therefore, young 
age has an unfavourable impact on prognosis in breast cancer.  
 
3.5. Scatter plots and correlation coefficient  
In order to inspect the relationship between different tumour biomarkers and the 
output (state of nodal involvement), data scatter plots for each two pairs of inputs are 
plotted. These scatter plots are good indicators of potential associations between 
each two pairs of markers and the degree of output separability based on each set of 
two biomarkers. 
Data scatter plots for all the two group combinations of input variables with regard to 
data scatter plots for all the two group combinations of input variables with regard to 
their corresponding output are illustrated in Figures 3.1 and 3.2. In Figure 3.1, the 
marker combinations including only continuous input variables are illustrated, while 
in Figure 3.2, at least one of the biomarkers have discrete values. The axis labels in 
each subfigure show the corresponding marker. In addition, output refers to the state 
of the nodal involvement where outputs with a value of 1 are indicated by circles ‘x’ 
while outputs equal to 0 are indicated by cross signs ‘o’. The continuous variables 
illustrated in these figures are standardised with regard to their mean and standard 
deviation by subtracting the vector mean from the vector and dividing it by its 
standard deviation. Therefore, each continuous variable maintains a zero mean and a 
unit standard deviation.  
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Figure 3.1: Data scatter plots for all two group combinations of continuous 
input variables with regard to their corresponding output where the output 
refers to the state of nodal involvement. The continuous variables are 
standardised such that they maintain zero mean and unit standard deviation. 
 
∘ Normal = 0 
⨉ Metastasis = 1 
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Figure 3.2: Data scatter plots for two group combinations of input variables 
with regard to their corresponding output where at least one of the biomarkers 
have discrete values. The output refers to the state of nodal involvement. The 
continuous variables are standardised such that they maintain zero mean and 
unit standard deviation. 
 
 
∘ Normal = 0 
⨉ Metastasis = 1 
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The scatter plots of the two-marker combinations in figures 3.1 and 3.2 illustrate the 
separability of output based on each set of biomarkers. From these figures, it is clear 
that the state of nodal involvement is not linearly separable with any of the 2-marker 
combinations. The complex nature of the marker relationship in the 2-dimensional 
figure is also evident from this figure. 
In order to evaluate these marker relationships numerically, the PCC explained in 
section 2.2.2 is computed for all the tumour biomarkers and the state of nodal 
involvement. These results are tabulated in Table 3.3. The PCC presented in this 
table takes a number between -1 to +1 for the measure of linear dependence between 
tumour biomarkers. A positive value represents a positive linear relationship while a 
negative one implies negative linear relationship and 0 suggests no linear relation 
between variables. The diagonal cells of the table have a value of 1 since they show 
the correlation of the tumour biomarker with itself. Additionally, this table represents 
a symmetrical matrix for PCC since for two variables   and  ,          
        . 
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Table 3.3: The Pearson correlation coefficient computed for all the tumour 
biomarkers and the state of nodal involvement 
 
Tumour 
size 
ER PR p53 Ki-67 Age 
Nodal 
involvement 
Tumour 
size 
1 -0.288 -0.472 0.109 0.111 -0.008 0.026 
ER -0.288 1 0.615 -0.265 -0.161 -0.058 0.202 
PR -0.472 0.615 1 -0.370 -0.214 -0.080 0.041 
P53 0.109 -0.265 -0.370 1 0.278 -0.141 0.011 
Ki-67 0.111 -0.161 -0.214 0.278 1 0.079 -0.079 
Age -0.008 -0.058 -0.080 -0.141 0.079 1 0.127 
Nodal 
involvement 
0.026 0.202 0.041 0.011 -0.079 0.127 1 
 
Results from Table 3.3 suggest some linear relation between ER and PR (PCC = 
0.615).  The degree of linear dependence of P53 and PR (PCC = -0.370) and tumour 
size and PR (PCC = -0.472) is also noticeable. From the correlation between the 
nodal involvement and other tumour markers indicated in the last row of the table, it 
is evident that there is no significant linear relation between markers and the output. 
These results however, do not necessarily provide any indication about the existence 
of any nonlinear interaction between the different markers and the output.  
From Figure 3.1 and Table 3.3, it is clear that there is little or no linear relation 
between the tumour biomarkers and the state of nodal involvement. This signifies the 
inefficiency of linear statistical classifiers such as LR in classifying the breast cancer 
data and suggests the need for nonlinear classifiers such as ANNs. 
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3.6. Summary  
In this chapter, the ALN status for predicting the breast cancer progression was 
explained and a novel set of markers for predicting the outcome was introduced. 
Although the presented markers have existed in breast cancer literature for a long 
time, this research proposes a novel relation between these markers and the state of 
ALN progression.   
The relationship between the presented biomarkers and breast cancer progression 
outcome was investigated from three different aspects including medical, visual and 
quantitative analysis. The medical aspect was covered in a medical literature about 
each individual marker. This also entailed a description of the biomarkers and their 
role in breast cancer progression. To show this relationship visually, scatter plots of 
the data were presented. These scatter plots illustrate the complex nature of marker 
relationships and the inseparability of the markers with respect to the cancer outcome 
in 2-dimensional space. Although it is not possible to visualise this relationship in 
higher dimensional spaces, it is expected that in higher dimensional spaces, the 
markers provide a higher degree of separability for patients with and without 
metastasis. To quantify the relation of markers and the outcome, the PCC is 
employed. PCC represents the degree of linear relationship between each two 
markers or each marker and the outcome. These results show little or no linear 
relation between the markers and the state of ALN progression. 
In the next chapter, an ANN architecture and evaluation method are proposed to 
predict the state of metastasis to the ALNs using the chosen biomarkers. These 
methods are chosen in combination to overcome some common problems of the 
commonly employed methods detailed in chapter 2. In addition, these methods are 
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chosen such that they address the requirements for classifying the ALN progression 
status using the chosen set of biomarkers. 
  
69 
 
 
 
 
 
Chapter 4 
4. A neural network approach for 
reliable breast cancer prediction 
4.1. Introduction  
As mentioned in chapter 2, some common problems exist in the most widely 
employed statistical and machine learning studies conducted in the field of cancer 
diagnosis. These include limitation of linear modelling, large data size requirement 
and several assumptions made about the input data. To address these common 
problems, this research exploits an ANN structure known as PNN. The PNN is 
employed to predict the state of metastasis to the ALNs using a breast cancer dataset 
from 108 patients. This dataset and the patient biomarkers employed to predict the 
nodal status have been explained in detail in the previous chapter. 
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 This chapter details the MLP structure as the most widely employed ANN in cancer 
studies, here used as the benchmark for the comparison of results. MLPs 
disadvantages and common issues in cancer studies are then covered. After that, an 
in depth explanation of the PNN; its structure and training algorithm are detailed. 
The final section of the chapter describes an error estimation method based on 
resampling, entitled as .632 bootstrap. The applied methods in conjunction with the 
employed dataset bring about a novel application of PNN in breast cancer prediction.  
 
4.2. Multilayer perceptron  
The MLP is a feed-forward ANN in which the data, entered at the input layer, 
propagate in one direction through the hidden layer(s) to the output layer (Figure 
4.1).  Hidden and output layers are composed of single units called perceptrons. Each 
perceptron in the MLP receives a set of inputs which are first weighted and then 
added together.  The resultant value is used to trigger an activation function that will 
map the combined inputs to an appropriate output response.   
In essence, the MLP can be deemed as a simple input-output model with connection 
weights as the free parameters. Such a model is able to represent a function 
describing the relationship between the inputs and outputs where the number of 
hidden layers and number of units in each layer can define the complexity of the 
function. Therefore, one critical issue in MLPs is defining an optimum number of 
hidden layers and their corresponding units such that the constructed function is 
complex enough to describe the relation between the inputs and outputs but not too 
complex, so that it maintains the ability to generalise for new data [62, 65]. The 
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number of neurons in the input and output layers is defined by the problem in hand. 
In the input layer, this is equal to the input space dimension while in the output layer, 
it is defined by the output categories.  
Learning of the input-output relationship in MLPs is performed by the adjustment of 
the connection weights linking the layers together. This is done via a training 
algorithm that is a predictive model which adjusts the weights by minimising the 
network error with respect to its weights. Back propagation (BP) [62] is the most 
widely implemented training algorithm applied for MLP training that is detailed in 
the next section.  
 
  
Figure 4.1: Structure of the MLP with one hidden layer 
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4.2.1. Back Propagation (BP) 
BP algorithm is employed to train the MLP using a sample set of data so that the 
network can predict a new input correctly. The principles of BP training are similar 
to perceptron’s training explained in 2.5.3. Generally speaking, this is performed by 
initialising the network weights randomly and computing the network output using 
the available input data. This output is then compared with the desired outcome and 
an error signal is computed which is then employed to construct an error function. 
Finally, the error function is minimised with respect to weights to adjust them such 
that the network provides a closer output to the desired outcome. This procedure is 
replicated several times, each round called an iteration, to obtain the optimum set of 
weights. 
BP algorithm consists of two passes of information: a forward and backward step. In 
the forward step, the predicted outputs   p corresponding to the given inputs of the 
layer yh for the p
th
 input pattern are evaluated using: 
            
 
   
           ( 4.1 ) 
where s denotes the s
th
 iteration (step) of the training process    is a vector of 
outputs of the hidden layer for the p
th
 input pattern, computed as: 
            
 
   
           ( 4.2 ) 
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where xip is the i
th
 element of the p
th
 input pattern, and wih and     are the connection 
weights linking the input-hidden and the hidden-output layers respectively. It should 
be noted that     and w0j are equal to 1 and correspond to each neuron’s bias with 
their associated inputs being equal to the bias value. The function is the nonlinear 
activation function (transfer function), commonly considered as a hyperbolic tangent 
sigmoid function in both hidden and output layers and hence represented with the 
same symbol for both layers: 
     
     
     
 ( 4.3 ) 
As mentioned in 2.5.2, this function is used for its special characteristics such as 
monotonicity and symmetrical output. When the forward pass is completed, an error 
signal   is computed by comparing the network’s outputs    with the desired 
response   . The error signal is then fed into a cost function to control the 
adjustments to the weights. Mean square error (MSE) is commonly used as the cost 
function which is drawn from maximising the likelihood of each data point         
in the training data defined as:
   
  
 
   
                 
 
 
   
 
    
( 4.4 ) 
where the cost function   is the mean of squared-error of the total number of output 
neurons   over the total number of training patterns denoted by   .     and     are 
the desired output and the network’s output respectively, resulting from the jth output 
neuron using the p
th
 input pattern.  
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In the backward pass, gradient descent (GD) algorithm is used for updating weights. 
In this method, the partial derivative of the cost function with respect to network 
weights is computed and the weights are adjusted accordingly. To explain this 
procedure clearly, one neuron from Figure 4.1 is considered and the amount of 
weight adjustment is computed for it. This can be easily generalised for the whole 
network. For simplicity, this neuron and its connections are illustrated in Figure 4.2. 
 
 
  
 
             
 
 
 
 
 
 
Figure 4.2: An output neuron j and its connections from a multilayer 
perceptron 
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As illustrated in Figure 4.2, neuron j receives the output signals of the previous 
layer’s neurons. These signals are weighted to produce the activation of the neuron j 
as: 
                  
 
   
 ( 4.5 ) 
where l is the number of inputs to neuron j. The first input y0=1 is the bias applied to 
neuron j. the neuron’s output oj(s) is computed by feeding the activation signal vj(s) 
into the transfer function φ: 
                ( 4.6 ) 
In each iteration, the weights are modified by         that is proportional to the 
partial derivative 
  
       
. Using he chain rule, this can be expressed as:  
  
       
 
  
      
 
      
      
 
      
      
 
      
       
 ( 4.7 ) 
Using the general form of the MSE cost function in ( 4.4 ) as   
 
 
   
    , this 
leads to: 
  
      
       ( 4.8 ) 
The second term in the right hand side of ( 4.7 ) can be obtained from          as 
      
      
    . 
The third term in the right hand side of ( 4.7 ) can be obtained using ( 2.33 ) as: 
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        ( 4.9 ) 
Finally, differentiating ( 4.5 ) with respect to the weights gives: 
      
       
       ( 4.10 ) 
Using equations ( 4.8 ) to ( 4.10 ), the equation ( 4.7 ) can be written as: 
  
       
         
 
             ( 4.11 ) 
The weight change is defined proportional to the partial derivative in ( 4.11 ) as: 
          
  
       
             ( 4.12 ) 
where β is the learning rate (step size) in BP and the local gradient       is defined 
as: 
      
  
      
 
  
      
 
      
      
 
      
      
         
 
        ( 4.13 ) 
The local gradient is a vector pointing along the steepest descent from the present 
point. A series of such steps (changing the weights in the direction of the local 
gradient) guarantees declining of the error and moving towards the minimum of the 
error surface. β defines the size of the steps in the direction of the steepest descent. 
While, a large β helps the algorithm to converge quickly towards the minimum, it 
might cause overstepping the answer. On the contrary, a small step may lead the 
algorithm to the solution, but it may require a long time and many iterations. 
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Therefore, an appropriate choice of the step size is important in achieving a desirable 
solution within a reasonable amount of time. This depends on the application in hand 
and is usually selected by experiment. It is also possible to decrease the step size as 
the algorithm progresses towards the minimum [62]. 
In general, the training algorithm progresses towards the solution in each iteration by 
feeding the inputs to the network and computing an error by comparing the network 
output and the targets. The weights are then adjusted according to the error function. 
The training stops when a minimum error is reached or a certain number of iterations 
are passed. These are called the stopping criteria which prevent the algorithm to 
proceed for a long time and overtrain. 
Although BP is widely employed for training the MLP, it has some limitations. The 
main limitations are the slow convergence of the BP and the high probability of the 
algorithm getting trapped in local minima on the error surface (the surface obtained 
from the cost function). These limitations can be obviated by using the second 
derivative of the error function in the scaled conjugate gradient (SCG) algorithm. 
4.2.2. Scaled conjugate gradient algorithm  
SCG algorithm, proposed by Moller [99], is an effective approach to perform 
supervised learning in feed-forward MLPs. SCG algorithm is a class of conjugate 
gradient optimisation techniques which is much faster than usual BP algorithms. The 
algorithm consists of a forward and backward step. The forward step is similar to BP 
and has been covered in the previous section.  
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In the backward pass, second partial derivatives of the cost function with respect to 
the network parameters, weights and biases, are computed and propagated back 
through the network. Second derivative of the MSE function in ( 4.4 ) with respect to 
the weight vector W is denoted as Hessian matrix H, computed as: 
     
      
   
 ( 4.14 ) 
where W denotes the network’s weight matrix obtained from concatenating the two 
layers of weights wih and whj. Using the second order derivative of the cost function 
provides additional information related to the curvature of the MSE cost function 
(error surface), and hence, results in faster and more accurate convergence to the 
minimum point compared to first order techniques, such as the standard BP, that use 
the first derivatives only.  
However, in conjugate gradient algorithm this is done at the cost of a high 
computational complexity as it performs a line-search to minimise the cost function. 
A line-search involves defining a search direction in the weight space and locating 
the minimum of the cost function along that direction [65]. In conjugate gradient 
algorithm, the weights at each layer are updated using the following recursion: 
             ( 4.15 ) 
where ds is the search direction at step s which is defined such that the component of 
the gradient parallel to the previous search direction is kept equal to zero, and hence, 
search directions are described as being conjugate.    defines the step size in each 
step which can be derived as: 
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 ( 4.16 ) 
where    is the gradient vector of the error surface at step s. From ( 4.16 ), it can be 
inferred that Hessian matrix H needs to be evaluated in each step in order to define 
the step size. This calculation is computationally demanding and therefore, is 
avoided in conjugate gradient algorithm by performing a line minimisation along the 
search direction to evaluate    in each step [65]. Nevertheless, a line-search is still 
computationally expensive as it needs the evaluation of the cost function at each line 
minimisation. SCG algorithm has been introduced as a way to avoid the line-search 
by evaluating the term     instead of using line minimisation to compute the step 
size   .     can be computed at a low computational cost by a method, introduced 
by LeCun et al. [100] which approximates the product of Hessian matrix with an 
arbitrary vector dm without computing the full Hessian. For computing    using 
(4.16), the Hessian must be positive definite; otherwise,    can become negative 
which would lead to an increase in the cost function at each weight update 
accordingly. SCG algorithm tackles this problem by modifying the Hessian as: 
        ( 4.17 ) 
where   is the old value of the Hessian matrix and    is its modified value. 
  represents a unit matrix multiplied by the positive coefficient  , where   is defined 
such that the new Hessian    would be positive definite. The training is completed 
when the system exceeds a specified minimum amount of gradient performance or a 
maximum number of iterations. These two stopping criteria are employed in 
conjunction to avoid overfitting and to provide a good generalization performance. 
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During the test process, test samples with unknown outputs to the network are fed 
into the input layer and the network’s classification outcome is computed using (4.1) 
and ( 4.2 ). The output would be in the range [-1 1], as the output neuron’s transfer 
function is a hyperbolic tangent bounded to the range [-1 1]. Outputs in the range [-1 
0] are interpreted as output 0 and [0 1] as output 1. The network outputs are then 
compared with the desired target values and the network’s performance is evaluated 
in terms of the percentage of the test samples classified correctly which is referred to 
as network’s accuracy.  
4.2.3. Advantages  
MLPs owe their extensive application in cancer prediction to several special 
characteristics in their theory and structure. Some of these advantages include: 
- MLPs are universal approximators. Therefore, they can realize any 
optimal decision boundary with arbitrary precision [101, 102]. 
- ANNs are capable of approximating the posterior probabilities. This 
property makes them a suitable approach for statistical analysis [103]. 
Although ANNs are capable of extracting complex and nonlinear relationships from 
data, they have some intrinsic limitations which have made their application in 
medical diagnosis controvertible [20, 36]. Some of these limitations are listed and 
explained in the next section to be tackled later on in the next chapters.  
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4.2.4. Problems with the existing MLP models in 
cancer prediction  
Numerous publications have been issued on the subject of neural network-based 
cancer prognosis, and yet none of them has presented a perfect solution to the 
problem. This mainly arises from the uncritical application of ANNs, and mainly 
MLPs, which has led to unpractical models for cancer prognosis. Neural network 
application in oncological diagnosis has been critically reviewed in statistical and 
neural network journals [20, 36, 74]. These publications have carried out a critical 
review on the problems with studies using neural network models in oncology. 
Some common problems encountered with the use of MLPs in cancer prediction 
include overfitting (the inefficiency of the network to generalize for new patients) 
and uncritical estimation of the true classification error of the networks. Choosing 
the appropriate network structure for the in-hand problem is also another issue which 
has not found a unique solution so far. These problems hinder the widespread 
practical application of neural networks in cancer prognosis. Below is a detailed 
argument of the mentioned problems which is the forerunner to better understanding 
the main problems addressed in this thesis.  
4.2.4.1. Overfitting  
The flexibility of neural networks in nonlinear mapping and estimating complex 
functions are two of the main advantage of ANNs which has made them widespread 
in cancer diagnosis. However, naive use of MLPs in cancer applications and lack of 
accurate model evaluation methods leads to overfitting [20]. 
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Overfitting or fitting implausible functions to the training data is one of the most 
common problems with the application of MLPs in cancer prediction. Overfitting is 
the inability of the network to generalize for unseen data which generally originates 
from fitting exceedingly complex functions to describe the probability of class 
membership of the data points at hand. In MLP neural networks, this occurs mainly 
due to the large ratio of the network parameters to the number of data points.  
Unfortunately, there exists no standard method for measuring and quantifying the 
amount of overfitting. However, there are methods devised to detect overfitting and 
avoid it. One indicator to examine whether the network overfits the data is the ratio 
of the number of parameters in the network to be adjusted to the data size. In ANNs 
literature, 5 or 10 data points are required for each free parameter in the network as a 
rule of thumb [104]. In many ANN studies applying MLP in cancer prediction, this 
ratio is even less than 2 which implies the significant amount of overfitting and the 
inability of the devised networks to generalise for new patients [20]. To avoid this 
problem, one can employ a large dataset that has the same statistics as the 
population. However, increasing the size of data in medical applications is a 
cumbersome task which sometimes requires considerable time and funds to collect 
the desired data from patients. A solution to assess and reduce overfitting in MLPs is 
cross validation (CV) [44]. In this method, the training data are randomly divided 
into two parts: the training set and validation set. The training set is used for training 
the network and the validation set is used to estimate the validation performance. 
This measure is estimated by testing the network with the validation set as it is being 
trained with the training data. The validation performance is monitored during the 
training process and the training is stopped when this performance reaches its 
minimum value.  This is shown in Figure 4.3.  
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In most training tasks, the validation performance is similar to the training 
performance at the beginning, up to a point where it takes an opposite direction and 
starts to increase as the training performance continues to decrease. This implies that 
the network has started to overfit the data from the point where the two performances 
take opposite directions as the network can no longer provide good performance for 
the validation set. This point is epoch 3 in Figure 4.3. 
 
 
Figure 4.3: In cross validation, the training data is divided into two parts: the 
training set and validation set. The validation performance is monitored during 
the training process and the training is stopped when this performance reaches 
its minimum value (best validation performance).   
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CV is not an optimum method because a part of the data are kept unseen to the 
network as the validation set and hence, the network is trained only with a part of 
data. This is especially problematic with small datasets as the patterns in the data 
must be unveiled only with a part of the small data.  
 
4.2.4.2. Error estimation  
The realistic error of the designed network can be determined by running the 
network for new inputs and comparing the generated outputs with the desired targets. 
For this purpose, two non-overlapping groups of data are used for training and 
testing the network. One major issue in training and testing the ANNs employed for 
cancer predictions is that datasets relating to cancer can contain a relatively small 
number of patients in comparison with the number of measured variables.  This 
limitation results in two problems in classification. First, the classifier will learn the 
existing patterns in the population using only a small number of samples. Second, an 
estimate of the accuracy of the classifier for new data can be only performed using 
the same small dataset. Using a small dataset for testing the designed network results 
in biased estimation of the classification error [20]. 
Several methods have been devised to employ the available data for training and 
testing the designed ANN. These error estimation methods have been discussed in 
section 2.7. A reliable and accurate error estimation method for evaluating the 
proposed ANNs in this study is fully discussed in this chapter in section 4.4. 
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4.3. Probabilistic neural networks  
 PNN is a special design of the RBF for dichotomous outputs. RBF networks 
typically are made up of three layers including input layer, a hidden layer with an 
activation function in the form of a nonlinear radial basis function and a linear output 
layer. The input data, provided to the network through the input layer nodes, is 
nonlinearly transformed into a high-dimensional hidden space by the basis functions. 
Afterwards, the response of the network is determined from a linear transformation 
of the hidden layer outputs. The PNN’s overall structure is similar to that of the 
RBFs. Moreover, the PNN classification framework follows the same principles as 
the RBF that is transforming the data nonlinearly into a high-dimensional hidden 
space. In the following sections, some principles of the dichotomous classification in 
the PNN, the Bayesian probability theory and its role in developing the PNN’s 
classification algorithm are explained in detail.  
4.3.1. Probabilistic framework for classification  
In a probabilistic approach to classification, features and classes are assumed as 
random variables for which a probability density function (PDF) can be estimated. In 
this context, learning from examples can be performed by estimating the PDF of the 
feature space and classes from the available data.  
 When dealing with a classification problem with two output categories, the output 
class can be viewed as a discrete random variable that is constructed as a binary 
vector   based on known class categories. Each element in   corresponds to an 
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observation (patient) and is either   for patients with metastasis in the ALNs or   for 
those with no metastasis. The ultimate goal of the classification is defining a 
decision rule in order to determine the probability of the output class random 
variable being equal to   or   for a new patient with known features and unknown 
diagnosis.   
Conventional learning from data in MLP training can be described from statistical 
viewpoint as maximum likelihood (ML) estimation. This happens as the network 
weights are adjusted during the training such that their fit to training data is 
maximised. In the context of probability, MLP gives a direct estimate of the 
posterior probability without estimating the prior or conditional probabilities.  Unlike 
MLP, learning in PNN is based on Bayesian statistics. In Bayesian statistics, learning 
is based on probability distributions that are either known or can be estimated. These 
probability distributions describe the uncertainty being learned from the existing 
relationships in the data.  
Bayesian statistics employs the well known Bayes theorem as a means to obtain a 
probabilistic model of the observed data. In this section, Bayes theorem is described 
briefly. Then, the PNN approach to classification using Bayes theorem is detailed. 
4.3.2. Bayesian probability theory 
According to Bayesian probability theory, the probability of an observation 
belonging to class O = j (j=1,2 for a binary classification problem) can be expressed 
using Bayes theorem. This is expressed in ( 4.18 ) and ( 4.19 )  where          
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denotes the class-conditional PDF also known as likelihood function      ,     
   denotes prior probability (   ),       denotes the evidence (a normalizing constant 
to ensure that the total probability is one and          denotes the posterior 
probability: 
         
               
    
 
        
    
  ( 4.18 ) 
                     
     
 ( 4.19 ) 
where                   is the input vector to be classified as belonging to output 
class      ; having two classes        .  
The probability of the output being equal to   or   for a new patient with known 
features and unknown diagnosis is denoted as          which is the posterior 
probability of the class   given the input  . Based on Bayes theorem in ( 4.18 ) and 
(4.19), posterior probability can be derived from two quantities:  prior probability 
and the class-conditional probability density function. These two quantities can be 
derived by using sample data with known input features and output classes. 
The prior probability        is the probability of randomly selected samples with 
class     from a set of data. For a two class problem with equal probability for 
each class, the probability of randomly selecting a sample belonging to class   is 
50%. Hence, the highest error given all samples are classified as   is 50%. The prior 
probability becomes noticeable in classification problems having classes with 
different priors. For example, in a binary classification problem with class   having a 
prior probability equal to     and class   with prior equal to    , taking pure chance 
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of assigning class   to all inputs results in     error. Therefore in this case, the 
maximum error with a dumb classifier is 80% and not 50%.  
The class-conditional PDF is the conditional density of input   belonging to class 
    or the likelihood of the class     given the input   and is denoted as 
        . A new observation can be classified using Bayes probability theory by 
assigning it to the class with the highest posterior probability. This minimises the 
misclassification probability and obtains the Bayes optimal decision [44]. 
4.3.3. Bayesian Analysis for PNN 
The PNN classifies each new pattern as a member of one of the two or more output 
classes by modelling a Bayesian classifier. This is carried out by computing the 
posterior probability of a new pattern given different output classes and assigning it 
to the class having the largest posterior probability. As mentioned before, Bayes’ 
theorem allows the calculation of the posterior probability by computing the 
multiplication of conditional probability (likelihood) and prior probability divided by 
a normalizing constant. The constant P(X) in the denominator of ( 4.18 ) is the 
probability of the available input data irrespective of the knowledge about the output 
distribution. Hence, it can be eliminated as it is a common factor in the comparison 
of different posterior probabilities. Therefore, ( 4.18 ) can be simply stated as:   
                                         ( 4.20 ) 
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The prior probability is known and in the PNN with two output classes is considered 
as the relative frequency of training samples from each class.  Thus, the key issue in 
computing the posterior probability is estimating the probability densities of the 
training patterns belonging to each class.  
In the PNN, this is carried out using Parzen-Window density estimation, in which the 
PDF of a set of given patterns is estimated in a nonparametric manner by 
superimposing a set of kernels (window functions) placed on each data point [105]. 
Therefore, assuming two groups of data to be classified, the PDF of each group fj(X) 
can be estimated as: 
       
 
    
    
      
 
 
 
   
  
   
 ( 4.21 ) 
where xip is the p
th
 training pattern and the index i refers to each element of the n-
dimensional input vectors. Pj indicates the number of training patterns in each class. 
k(.) is the kernel (window function) placed on each training pattern and its width is 
specified by s, denoted as “spread” in the PNN. 
In the PNN, classification is carried out by estimating the fj(X) for each group. A 
PNN consists of four layers including input, pattern, summation and output layers 
[24]. The pattern layer consists of RBF nodes. Therefore, PNN is considered as a 
variant of RBFs.  
A PNN structure with a two-class output is illustrated in Figure 4.4. For training the 
network, the training samples xip are presented at the input layer. During the training 
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mode, the weights between the input and pattern layers wip are set equal to the 
training samples as: 
        ( 4.22 ) 
Therefore, the size of input and pattern layers are determined by the input vector’s 
dimension   and the number of training samples   respectively, where the number of 
training patterns P is the sum of the number of samples in two groups, P1 and P2. 
The size of summation layer is determined by the number of groups to be classified. 
Hence, in the present application the summation layer consists of two units for which 
the weights     are adjusted to   if the training pattern belongs to the class 
associated with that unit and is   otherwise. Thus,     is formulated as: 
     
                        
                      
  ( 4.23 ) 
Applying PNN’s weight structure to ( 4.21 ) obtains: 
       
 
    
       
      
 
 
 
   
 
   
 ( 4.24 ) 
A multivariate Gaussian kernel is commonly used in a Parzen-Window PDF 
estimator and hence       in ( 4.24 ) can be represented as: 
        
 
    
 
     
          
        
 
   
 
 
   
 
   
 ( 4.25 ) 
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where s is the Gaussian kernel bandwidth (spread). The implications of the spread 
and the method for deciding an appropriate value for the spread are discussed in the 
section 4.3.3.1, “Spread”. 
Finally, a comparison is made at the output layer between the summation of kernel 
functions obtained for different classes, fj(X) for j=1,2,  and the class with the highest 
value would be assigned to the input data. Therefore, the output decision function 
can be represented as: 
   
                                            
                                           
  ( 4.26 ) 
 
Figure 4.4: A two-class output PNN structure 
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4.3.3.1. Spread  
Spread is the scaling factor of the window function in Parzen Window estimation 
which determines the width (standard deviation) of the Gaussian kernel. It is also 
called the smoothing factor or bandwidth by some authors. Parzen Window density 
estimation can be viewed as the sum of window functions centred at each 
observation. While the kernel functions k determine the shape of the windows, the 
spread s determines their width. Spread controls the appearance of the density 
estimate fj(x) in ( 4.25 ), which in turn signifies the amount of separation of the input 
patterns.   
The effect of varying the spread on the shape of the fj(x) is illustrated in Figure 4.5, 
Figure 4.6 and Figure 4.7 for spread values of 0.5, 1 and 2 respectively.  A small 
spread value (  ) would result in probability density estimates that are too narrow 
with a sharp peak as illustrated in Figure 4.5 for s = 0.5.  On the other hand, a large 
value for the spread gives rise to smoothed boundaries that do not separate the data 
effectively (Figure 4.7).  The decision boundaries and the degree of generalisation 
capacity of the PNN depend on the choice of the spread value. 
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Figure 4.5:  Three 2-dimentional Gaussians with s = 0.5 
 
 
Figure 4.6:  Three 2-dimentional Gaussians with s = 1 
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Figure 4.7:  Three 2-dimentional Gaussians with s = 2 
 
Silverman’s rule-of-thumb bandwidth selection method is used for automatic 
derivation of spread where the spread s = 1.06 P
−1/5
 σ, with σ the sample standard 
deviation, and P the size of training set [106]. In effect, pattern and summation 
layers of a PNN form a Parzen-window PDF estimator in which a set of Gaussian 
windows centred at each training pattern are superimposed to estimate the PDF of 
the training data. 
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4.4. The evaluation procedure 
Non-realistic estimation of the misclassification probability is a common problem in 
most studies that have employed ANN for cancer prognosis. This has resulted in the 
underestimation of the prediction error rate of many proposed models [20]. This 
problem originates from the limited dataset which is a common issue in most 
medical applications. The attempt in this study has been to analyse different methods 
of error estimation and to quantize the amount of underestimation in various models. 
The ultimate goal is to introduce a standard method for defining the prediction error 
in neural network-based prognosis which would be compatible with limited datasets. 
To achieve this aim, bootstrap .632 has been employed to evaluate the predictive 
accuracy of the designed PNN. In the following section, a comprehensive 
explanation of this technique is provided.  
4.4.1. Bootstrap .632 
In bootstrap method, a new dataset, called bootstrap sample, is generated by 
uniformly sampling P data points with replacement from the original dataset of size 
P. Therefore, the bootstrap sample has the same number of data points as the original 
data while some data points might appear in the new set more than once and some 
might not be included. This new data are then used to train the classifier and those 
data points left out from the new set are exploited to test the classifier. In the basic 
bootstrap, the final classifier error is estimated by replicating this procedure for   
times producing    new datasets with             and averaging over all the 
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obtained errors.   is the number of bootstrap replications. By sampling the dataset 
with replacement, the probability of any data point  , not being sampled after   
times is: 
              
 
 
        .    ( 4.27 ) 
Thus, the error estimation by basic bootstrap tends to be pessimistic (biased upward). 
The .632 bootstrap has been introduced to overcome this upward bias by computing 
the error using a weighted combination of the upward-biased basic bootstrap and 
downward-biased apparent errors [107]. This is formulated as: 
       A    (1 A)    ( 4.28 ) 
where E
.632 
, E
b
 and    are .632 bootstrap, basic bootstrap and apparent errors 
respectively and weights are defined as A = 0.632 and 1-A = 0.368. The upward bias 
of basic bootstrap and downward bias of apparent errors are mitigated in .632 
bootstrap by employing a convex combination of the weights A and 1-A, where 
convex means that the weights used to combine the two errors are nonnegative and 
give one when added together [108]. The .632 bootstrap has been shown to provide a 
reliable error estimate for neural network classifiers with a small sample size and 
non-zero apparent error [28]. Hence, the .632 bootstrap is employed as the error 
estimation method for both MLP and PNN in this study. 
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4.5. Choosing the best marker combination for 
diagnosis 
Breast cancer metastasis is a complicated process. Each biomarker can only 
represent certain aspects of the disease. Therefore, a combination of markers is 
required to predict the metastasis. The biomarkers themselves have an impact on 
each other making the prediction task even more complex. Hence, it is important to 
choose a combination with markers that each represent an aspect of the disease and 
at the same time, do not have an overlap in the knowledge they represent about the 
disease. The information overlap provided by different markers complicates the 
prediction process and may expose the developed model to loss of generalisation. 
This may happen as a model with large number of input markers becomes more 
complex and overfitted to the presented patients with low generalisation for new 
ones. In addition, employing more markers for prediction is more costly to the health 
centres.  
From the technical view point, the accuracy of the likelihood          estimation 
in ( 4.18 ) depends on the number of available samples: the larger the sample 
population, the closer the likelihood is to the true conditional probability of the 
population. This is also affected by a problem known as the curse of dimensionality.  
This means that the number of samples needed to estimate the likelihood increases 
exponentially with the number of available features for classification [109]. 
Therefore, it is important to choose only a selection of features that have a 
significant effect on the classification accuracy.  
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In addition, in the medical domain, measuring each biomarker means more cost and 
time to the laboratories. Therefore, obtaining the best prognosis based on the least 
number of features is desirable. There are myriad of feature selection methods for 
neural networks available in the literature. Each selection method uses a different 
criterion to choose the best features among several features or discard the ineffective 
features from the feature set. However, the most effective method in choosing the 
best selection of features is testing all the possible combinations of them and 
selecting the most effective feature or combination of features. 
 
4.6. Summary  
This chapter has presented the individual methods employed for classification of the 
breast cancer dataset and evaluation of the outcome. Among various ANN 
architectures, MLP and has been explained as the most widely used method for 
cancer prediction. Two learning algorithms for the MLP including the BP and the 
SCG have been covered in this chapter. BP is extensively implemented for training 
MLPs. However, it suffers from some limitations such as local minima. These 
limitations can be obviated partly by using conjugate gradient methods.   
Nevertheless, MLPs suffer from some common drawbacks including network’s 
complexity, numerous network variables required to be optimised and random 
weight initialisation.  
Afterwards the PNN has been proposed as the classification method in this analysis 
as it offers some unique characteristics in this research. The PNN addresses some 
common issues in classification using limited and complex datasets available for 
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breast cancer prediction. The PNN minimises the misclassification probability and 
obtains the Bayes optimal decision by computing the posterior probabilities using the 
model of a Bayesian classifier. The only parameter to be adjusted in the PNN is 
spread that has been explained in detail in section 4.3.3.1. The spread determines the 
degree of generalisation capacity of the PNN and hence, apt choice of the spread 
plays a significant role in accurate classification of both the available data and the 
unseen data.  
To address the non-realistic estimation of the misclassification probability as a 
common problem in most studies using ANN for cancer prognosis, .632 bootstrap 
has been proposed as an accurate and reliable error estimation method. .632 
bootstrap has been explained in detail in this chapter. It is a part of the resampling 
estimation method and an improvement over the basic bootstrap which obtains low 
bias and low variance especially in conjunction with small datasets that addresses the 
gap in accurate and reliable error estimation for small size breast cancer datasets. 
In the next chapter, the results of the PNN are compared with a feed-forward MLP. 
In addition, to choose a reliable error estimation method for the ANNs employed in 
this study, the variance of accuracies obtained by .632 bootstrap, 5-fold cross 
validation and holdout methods are computed and compared in chapter 5. 
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Chapter 5 
 
5. Experimental results and 
analysis  
5.1. Introduction  
In this chapter, the results achieved by two ANN structures - the PNN and the MLP 
are applied to the six markers presented in Tables 5.1 and 5.2. The first section of the 
chapter will describe the distinct subsets of chosen markers and how they are coded 
to investigate and compare the predictive importance of individual markers and their 
potential interaction with each other.  
In the second section, the method of .632 bootstrap error estimation is compared 
with the performance of holdout and 5-fold CV methods for both PNN and MLP. 
These methods are typically chosen as the prevalent evaluation methods employed in 
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breast cancer studies using ANN [20].   The comparison is performed by evaluating 
the variability of error obtained from the MLP and the PNN over 100 runs.  
After choosing the best error estimation method for the PNN and the MLP, the 
results achieved by these two ANN structures applied to all marker combinations 
presented in Table 5.1 will be tabulated. Finally, the best marker combinations will 
be chosen.  
 
5.2. Biomarker combinations  
Distinct subsets of the six biomarkers, listed in chapter 3, are devised in the form of 
1, 2, 3, 4, 5 and 6-marker combinations to present to the designed ANNs. These 
combinations are coded with numbers 1 to 63 for convenience. These marker 
combinations and their corresponding group numbers are displayed in Table 5.1. In 
this table, the first column indicates the combination group number while the 
markers considered in the study are listed in the first row. The following rows of the 
table have a value of 1 underneath for the markers already included in the 
combination and 0 for the markers not included.  Using different marker 
combinations allows for better importance evaluation of different subsets for nodal 
prediction and also comparison of the predictive importance of individual markers 
and their potential interaction with each other.  
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Table 5.1 All possible combinations of the 6 biomarkers coded with numbers in 
the first row and indicated by 1 and 0 for the marker(s) included in the 
combination and not included respectively 
Group 
number 
Tumour 
size 
ER PR p53 Ki-67 Age 
1 0 0 0 0 0 1 
2 0 0 0 0 1 0 
3 0 0 0 1 0 0 
4 0 0 1 0 0 0 
5 0 1 0 0 0 0 
6 1 0 0 0 0 0 
7 0 0 1 0 0 1 
8 0 0 0 0 1 1 
9 0 0 0 1 0 1 
10 0 0 0 1 1 0 
11 0 0 1 0 1 0 
12 0 0 1 1 0 0 
13 0 1 0 0 0 1 
14 0 1 0 0 1 0 
15 0 1 0 1 0 0 
16 0 1 1 0 0 0 
17 1 0 0 0 0 1 
18 1 0 0 0 1 0 
19 1 0 0 1 0 0 
20 1 0 1 0 0 0 
21 1 1 0 0 0 0 
22 0 0 0 1 1 1 
23 0 0 1 0 1 1 
24 0 0 1 1 0 1 
25 0 0 1 1 1 0 
26 0 1 0 0 1 1 
27 0 1 0 1 0 1 
28 0 1 0 1 1 0 
29 0 1 1 0 0 1 
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Table 5.1 continued  
Group 
number 
Tumor 
size 
ER PR p53 Ki-67 Age 
30 0 1 1 0 1 0 
31 0 1 1 1 0 0 
32 1 0 0 0 1 1 
33 1 0 0 1 0 1 
34 1 0 0 1 1 0 
35 1 0 1 0 0 1 
36 1 0 1 0 1 0 
37 1 0 1 1 0 0 
38 1 1 0 0 0 1 
39 1 1 0 0 1 0 
40 1 1 0 1 0 0 
41 1 1 1 0 0 0 
42 0 0 1 1 1 1 
43 0 1 0 1 1 1 
44 0 1 1 0 1 1 
45 0 1 1 1 0 1 
46 0 1 1 1 1 0 
47 1 0 1 0 1 1 
48 1 0 1 1 0 1 
49 1 0 1 1 1 0 
50 1 1 0 1 0 1 
51 1 1 0 1 1 0 
52 1 1 1 0 0 1 
53 1 1 1 0 1 0 
54 1 1 1 1 0 0 
55 1 1 0 0 1 1 
56 1 0 0 1 1 1 
57 0 1 1 1 1 1 
58 1 0 1 1 1 1 
59 1 1 0 1 1 1 
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Table 5.1 continued  
Group 
number 
Tumour 
size 
ER PR p53 Ki-67 Age 
60 1 1 1 0 1 1 
61 1 1 1 1 0 1 
62 1 1 1 1 1 0 
63 1 1 1 1 1 1 
 
The ‘Group number’ in the above table will be frequently referenced throughout this 
and the next chapter to reference each marker combination. 
 
5.3. Choosing a reliable network evaluation 
method 
In this section, three network evaluation methods for the designed ANNs are 
compared. Evaluating the classifier performance for DSSs is normally carried out by 
estimating the area under curve (AUC) of the receiver operating characteristic (ROC) 
curve. The ROC is a plot of classifiers’ true positive rate (TPR) against its false 
positive rate (FPR). The TPR is defined as the sensitivity of the classifier while the 
FPR is defined as              . Sensitivity and specificity will be described in 
the next section as the performance indicator for the designed ANNs. In this section, 
the focus is on estimating the classifier’s AUC with a limited sample size. This has 
been previously addressed for linear classifiers [28, 110]. For ANN classifiers, the 
problem of AUC estimation with limited data size has been tackled by Sahiner et al. 
[28, 111]. 
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To obtain an estimate for the ANN’s AUC, the network is trained with a part of the 
available data and tested with the remaining data, kept unseen to the network. The 
predicted AUC (   ) is therefore an estimate of the true AUC when the network 
trained with N samples tested with the true population. To assess the reliability of 
the    , the training and test experiments should be repeated for N times.  The 
mean and standard deviation of the predicted AUC are then computed to provide a 
measure for comparing the reliability of different evaluation methods and estimating 
the network’s performance: 
        
 
 
      
 
   
 ( 5.1 ) 
          
 
   
                 
 
   
 ( 5.2 ) 
where       is the predicted AUC for the network evaluated with m
th
 method in the 
n
th
 experiment. Running the experiment for N times is similar to a Monte Carlo 
simulation in that the process is replicated several times and the mean and standard 
deviation of the results are computed and assessed as a reliability measure. In Monte 
Carlo method, the experiments are repeated each time by drawing a sample from the 
true population. This is possible only when a there is access to the true population or 
its distribution so that different samples would be available to carry out the 
experiments. However, in this thesis, the sample size is limited and the data 
distribution is unknown. Therefore, each experiment should be run by applying 
different training and test data that are obtained by sampling from the available 
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dataset. The number of times that the experiments should be carried out are set to 
N=100. In the following sections, the approach for obtaining the AUC for the three 
evaluation methods evaluated in this research will be explained. 
5.3.1. Holdout  
For holdout estimate of the ANN performance with a dataset of size P, the data 
should be divided into two parts called training data Ptrain and test data Ptest=P- Ptrain. 
The process of dividing data is carried out for N=100 times and the average and 
standard deviation of the AUC are obtained.   
5.3.2. K-fold Cross validation 
Another method that is considered for estimating the ANN performance is K-fold 
CV. To predict AUC in this method, the data are partitioned into K parts. Each part is 
then chosen as the test data while the network is being trained with the rest of the 
data. The final AUC is predicted by averaging over the results obtained for each part: 
      
 
 
        
 
   
 ( 5.3 ) 
Similar to holdout method, the process of data partitioning is repeated for N=100 
times and the average and standard deviation of the AUC is obtained. 
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5.3.3. .632 Bootstrap  
Considering               as the available data of size  , where the bold letter   
denotes a set of data and italic letters    represent a data vector (i.e. a patient 
information of different biomarkers and age), the true distribution of data can be 
considered as  . In bootstrap, an empirical distribution of    is considered such that 
each    has a probability of    . A bootstrap sample indicated by  
   
    
   
    
   with size   can be created by sampling with replacement from   or 
in other words, randomly sampling from the empirical distribution   . As mentioned 
in section 4.4.1, the classifier performance obtained from the bootstrap samples is 
biased. In order to estimate the true performance of a classifier in bootstrap method, 
this bias should be computed and subtracted from the bootstrap performance [112].  
Since the reliability of different error estimation methods is being measured by AUC, 
a AUC (Strain, Stest) is chosen to represent the AUC of a classifier when trained with 
Strain and tested with Stest. Considering B bootstrap datasets represented as 
          , each set is of size  , obtained by randomly sampling with replacement 
from the original dataset  , can be represented as          
    
     
   . With 
this description, there exists a subset of dataset   which is not included in     
bootstrap sample    , indicated here as      . The performance of the classifier can 
then be obtained by training with bootstrap sample     and testing with the 
remaining samples      , i.e.               . The final AUC, obtained from B bootstrap 
samples is computed by averaging over all the computed bootstrap results as: 
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 ( 5.4 ) 
where      is the bootstrap AUC. As discussed in section 4.4.1 [112], the classifier 
performance obtained by this method is biased upward (pessimistic). To remove this 
upward bias, the .632 bootstrap AUC is computed as the combination of bootstrap 
AUC and the apparent AUC. The apparent AUC can be achieved by training and 
testing the classifier with all available data as:   
              ( 5.5 ) 
From equations (4.10) and (4.11), the .632 bootstrap AUC is estimated by combining 
the optimistic apparent AUC and pessimistic bootstrap AUC as: 
                                ( 5.6 ) 
5.3.4. Evaluation methods for the PNN 
To investigate the reliability of .632 bootstrap in estimating the output error of the 
PNN, it is compared with the two commonly employed error estimation methods in 
ANNs - 5-fold CV and holdout methods. For this purpose, the network is run for 100 
times for each of the 63 possible marker combinations and the estimated AUC by 
.632 bootstrap, 5-fold CV and holdout methods are computed. Table 5.1 shows these 
63 possible marker combinations including subsets of samples with 1, 2, 3, 4, 5 and 
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6 dimensions. For each of these dimensions, the three error estimation methods are 
compared in Figure 5.1 in the form of boxplots of the computed AUCs over 100 runs.  
The x-axis in Figure 5.1 shows the input dimension (number of markers included in 
the combination) and the y-axis is the computed AUC. For .632 bootstrap error 
estimation in the PNN, B = 50 bootstrap replications is used as this number is proved 
to be sufficient for most applications [75].  
 
Figure 5.1: The comparison of different error estimation methods for the PNN. 
These methods include .632 bootstrap, 5-fold cross validation and holdout 
methods for which the variability of the AUC is illustrated by boxplots. The 
Input Dimension on the x-axis shows the number of markers used as the input 
of the PNN. 
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In the above figure, the horizontal line in each box shows the median of the results 
for each error estimation method while the length of the lines show the degree of 
dispersion of the results. The ‘+’ signs out of the boxes show the outlier values. The 
boxplots in this figure illustrate the high variability and existence of outliers when 
computing the AUC using holdout method. This variability is reduced when using the 
5-fold CV and is the least when using .632 bootstrap. Regarding the medians of the 
results illustrated in Figure 5.1, it is clear that the median for .632 bootstrap is larger 
than that of 5-fold CV and holdout methods. Even so, the medians of all of the 
compared error estimation methods for the 3, 4, 5 and 6-marker combinations are 
further apart than those of the 1 and 2-marker groups. 
In addition, the AUC variability is illustrated for all combinations in Figure 5.2. In 
this figure, the x-axis shows the group numbers which refers to the group numbers 
defined for each marker combination in Table 5.1. The length of each line shows the 
variability of the AUC while the median is demonstrated with circles. Each sub-
figure in Figure 5.2 includes only combinations with the same number of markers. In 
this figure, the circles show the median of the results while the lengths of the lines 
represents their dispersion.  
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This figure illustrates that the AUC variability is high for holdout method for all the 
combinations of the same dimension and is significantly low for the .632 bootstrap 
method. The difference in the median of different error estimation methods shows 
that .632 bootstrap achieves higher median compared to the other two in most 
combinations. Examining each subgroup in Figure 5.2 reveals that for the first two 
subgroups including the 1 and 2-marker combination groups respectively, the 
medians of results for all error estimation methods are close to each other. For the 
last three subgroups in this figure showing the 3, 4, 5 and 6-maerker combination 
groups, the medians are further apart. Nevertheless, the median for the 5-fold CV 
and holdout methods are close for all marker groups. 
5.3.5. Evaluation methods for the MLP 
The reliability of .632 bootstrap in estimating the output error of the MLP is 
investigated by comparing .632 bootstrap with 5-fold CV and holdout methods. 
Similar to the comparison employed in the PNN, the variability of MLP AUC over 
100 runs, estimated by these three error estimation methods, is computed for each of 
the 63 possible combinations. To perform .632 bootstrap error estimation, B = 50 
bootstrap replications is used.  
The comparison results for combinations with different input dimensions are 
illustrated in Figure 5.3. These results are showed in the form of boxplots to clearly 
demonstrate the difference between the variability of results obtained by different 
methods. The x-axis in Figure 5.3 labelled as the “Input Dimension” refers to the 
number of markers in each group while the y-axis shows the AUC. 
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Figure 5.3: The comparison of different error estimation methods for the MLP. 
These methods include .632 bootstrap, 5-fold cross validation and holdout 
methods for which the variability of the AUC is illustrated by boxplots. The 
Input Dimension on the x-axis shows the number of markers used as the input 
of the PNN. 
There are similar trends in Figure 5.3 and Figure 5.1 for the variability and the 
median of the results for different error estimation methods over different marker 
groups. 
As it can be seen in Figure 5.1 and Figure 5.3, there are similar trends in PNN and 
MLP for the variability and the median of the results for different error estimation 
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methods over different marker groups. Nevertheless, comparing these two figures 
reveal that the results for the MLP in Figure 5.3 maintains higher number of outliers 
compared to those provided by the PNN in Figure 5.1. In Figure 5.3, the variability 
of the results obtained by holdout method is significantly higher than that of the 5-
fold CV and bootstrap. Among the latest two, .632 bootstrap obtains the lowest 
result variability. The median of the results for .632 bootstrap is slightly lower than 
that of the 5-fold CV and holdout methods for the 1-marker combination group. This 
trend is reversed for the rest of the input dimensions while the difference of median 
between .632 bootstrap and 5-fold CV and holdout methods is further apart for larger 
input dimensions. 
Results in Table 5.4 illustrate the AUC variability obtained by the MLP evaluated with 
the .632 bootstrap, 5-fold CV and holdout methods for all combinations. The x-axis 
shows the group numbers defined for each marker combination in Table 5.1. The 
length of each line shows the variability of the AUC while the median is 
demonstrated with circles. Each sub-figure in Table 5.4 only includes combinations 
with the same number of markers.  
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This figure illustrates that the AUC variability is high for holdout method for all the 
combinations of the same dimension and is significantly low for the .632 bootstrap 
method. The difference in the median of different error estimation methods shows 
that .632 bootstrap method can achieve higher median compared to 5-fold CV and 
holdout method in most combinations. Examining each subgroup in Figure 5.2 
reveals that for the first two subgroups that include the 1 and 2-marker combination 
groups respectively, the medians of results for all error estimation methods are close 
to each other. For the last three subgroups (3, 4, 5 and 6-maerker combination 
groups), the medians are further apart. Nevertheless, the median for the 5-fold CV 
and holdout methods are close for all marker groups. 
 
5.4. Neural network evaluation for breast 
cancer prediction 
In this section, the predictive ability of the designed networks is evaluated using 
sensitivity, specificity and accuracy. Sensitivity represents the ratio of the correctly 
diagnosed patients with metastasis to the total number of patients diagnosed with 
metastasis: 
                 
  
     
 ( 5.7 ) 
This means that the denominator is obtained by summing the number of both 
correctly and incorrectly diagnosed patients. Specificity denotes the same ratio for 
the correctly diagnosed patients without metastasis: 
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 ( 5.8 ) 
Accuracy is defined as the ratio of correctly classified cases to the total number of 
classifications, computed as:  
              
     
           
   ( 5.9 ) 
where TN, TP, FP and FN percentages respectively stand for: 
- True negative:    the percentage of normal samples classified as normal  
- True positive:     the percentage of cancer samples classified as cancerous 
- False positive:    the percentage of normal samples classified as cancerous 
- False negative:   the percentage of cancer samples classified as normal 
Sensitivity and specificity values reported in this study are rounded to the nearest 
integer and expressed in percentages. While it is desirable to have both sensitivity 
and specificity values at maximum of 100%, the associated risk of each of these 
parameters is different. A high sensitivity rate is more desirable than a high 
specificity rate. This is because the sensitivity indicates the number of correctly 
diagnosed metastasis cases which need auxiliary dissection and hence, a lower rate 
of mortality. On the other hand, the specificity is an indication of correctly classified 
normal patients who do not need a dissection and hence, a lower morbidity rate by 
reducing the number of unnecessary dissections. While keeping both mortality and 
morbidity rates at a low level is valuable, it is obvious that lower mortality is more 
advantageous to patients than lower morbidity. 
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Apparent error is also computed for each network. It indicates how well the network 
can separate the training data. Low apparent error indicates the efficiency of the 
network in classifying different categories in training data. However, low apparent 
error does not always come with low test error, since low apparent error can also 
imply that the network is over-trained. This means that the network has learnt some 
specific patterns in the training set which is not common to all patterns in general 
and eventually results in a small apparent error but a large test error.    
5.4.1. PNN results 
The prediction results obtained by the PNN for classifying node positive and 
negative tumours using all different combinations of input biomarkers are tabulated 
in Table 5.2. The group number in the first column of this table refers to the group 
numbers for each marker combination defined in Table 5.1. This table demonstrates 
the sensitivity, specificity, accuracy and training error computed for each group of 
markers using the designed PNN.  
The inputs of the PNN are normalised to the range [0 1]. This normalisation is only 
performed for the variable vectors age and tumour size since p53 and Ki-67 are 
already within this range and ER and PR are discrete variables. The normalisation is 
carried out by subtracting the vector minimum from the vector and dividing it by its 
range (i.e. the difference between the vectors’ maximum and minimum).  This 
normalisation is essential to the accurate performance of the PNN as the input 
variables are combined in the PNN via a distance kernel function. With such 
functions, the range of the variables affects their influence on the outcome. Hence, if 
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one input is within the range of 0 to 1 and another input has a larger range such as .5 
to 5.5, the contribution of the second input to the distance overshadows the first 
input. Therefore, it is important to normalise the input variables such that their 
variability is a reflection of their significance. Because this is an exploratory study in 
which the aim is to identify the importance of each variable in determining the 
outcome, the inputs are normalised to the same range. 
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Table 5.2: Nodal predictive accuracy of entire marker set and its different subsets 
assessed by PNN 
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
1 51 52 56 37 
2 52 52 57 35 
3 57 64 61 34 
4 74 66 51 47 
5 54 53 55 42 
6 53 65 59 37 
7 50 52 56 34 
8 62 52 64 23 
9 52 56 63 21 
10 54 52 58 26 
11 54 51 55 34 
12 64 64 56 35 
13 59 55 61 31 
14 52 53 53 39 
15 51 63 61 32 
16 56 57 54 42 
17 67 58 66 19 
18 52 53 58 26 
19 51 64 64 23 
20 59 63 58 34 
21 52 65 62 32 
22 62 52 67 11 
23 55 52 63 18 
24 51 52 61 23 
25 59 55 59 24 
26 70 50 67 13 
27 63 51 64 21 
28 52 55 60 27 
29 54 51 60 27 
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Table 5.2 continued  
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
30 52 61 53 34 
31 50 58 61 29 
32 60 53 65 13 
33 60 58 68 11 
34 54 52 61 18 
35 54 50 63 18 
36 55 50 58 24 
37 58 66 63 24 
38 52 58 67 15 
39 55 55 62 19 
40 50 66 67 18 
41 55 64 62 27 
42 65 53 67 11 
43 63 53 69 11 
44 53 52 64 13 
45 57 50 64 13 
46 52 51 61 23 
47 55 54 64 11 
48 52 50 65 11 
49 54 54 61 15 
50 60 55 67 13 
51 57 58 64 13 
52 65 55 66 11 
53 52 50 62 15 
54 61 62 68 16 
55 64 53 69 8 
56 55 51 68 8 
57 52 56 64 8 
58 55 51 67 5 
59 53 52 67 5 
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Table 5.2 continued  
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
60 53 52 64 8 
61 66 57 67 8 
62 52 65 67 10 
63 59 52 67 5 
 
Results in Table 5.2 show that among the individual markers in groups 1 to 6, group 
3 representing the p53 obtains the best prediction accuracy of 61%. Among the 2-
marker combinations in groups 7 to 21, tumour size and age in group 17 achieve the 
highest accuracy of 66%. In addition, two more combinations including group 8 with 
Ki-67 and age and group 19 with tumour size and p53 also gain high accuracies 
close to group 17. The existence of tumour size in these combinations displays the 
prediction potential of this marker in combination with other markers. Moreover, 
p53 and tumour size obtain a high accuracy among the 2-marker combinations which 
proves the potential of p53 for prediction both as an individual marker and in 
combination with other markers. 
Examining the 3-marker combinations in groups 22 to 41, group 33 with tumour 
size, p53 and age gains the highest accuracy of 68%. This result is very interesting as 
this group is a combination of the markers in groups 17 and 19 which achieved the 
highest accuracies in 2-marker combination groups. This can be explained by the 
interaction between the markers that can improve the accuracy when combined 
together.  
Amongst groups 42 to 56 which include 4-marker combinations, the highest 
accuracy is achieved by two combinations in groups 43 and 55 with an accuracy of 
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69%. These combinations have Ki-67 and age as common biomarkers. These two 
markers also give a high accuracy amongst 2-marker combinations. This clearly 
proves the potential of this combination of markers. It is noticeable that PR is 
missing from all the combinations with high accuracies. This can be explained by 
high correlation of ER and PR (PCC = 0.615) which may count for the compensation 
of PR by using ER.  
Groups 57 to 62 which constitute 5-marker combination groups shows the same 
accuracy except for the groups where either tumour size or p53 are taken out. This 
emphasizes the significant role of these markers in interaction with other markers to 
improve the prediction results.  
There exists a trend between the apparent error of different marker combinations and 
their accuracies. From Table 5.2, it can be observed that by adding more markers to 
the combinations, the accuracy increases while the apparent error decreases. This 
trend is disrupted in the 5 and 6-marker combinations where the apparent error 
decreases substantially to as low as 5% while the accuracy does not improve any 
longer and even decreases slightly compared to 4-marker combinations. This may be 
explained by network overfitting. Using more markers at the network input means 
more nodes and connections which may result in overfitting the network for the 
training data and loss of generalisation for new data.  
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5.4.2. MLP results  
The MLP structure designed in the present study consists of three layers: input, one 
hidden and an output layer. The number of nodes in the input is varied for each 
group of markers depending on the number of markers included as input. The 
number of nodes in the output layer is equal to one for all groups as it only depends 
on the number of groups to be classified. The number of hidden nodes is a free 
parameter which can be defined by trial and error considering the number of training 
patterns together with the input patterns’ dimension. Number of hidden nodes is 
chosen as twice the number of input units in accordance with the minimum of four 
nodes in the hidden layer. This is done by calling the INITNW function in MATLAB 
[113] which initialises weights using Nguyen-Widrow layer initialisation function 
[114].  
The prediction performance of the network is evaluated using the .632 bootstrap. The 
MLP results for all marker combinations are summarized in Table 5.3.  This table 
demonstrates the sensitivity, specificity, accuracy and training error computed for 
each group of markers using the designed MLP. To avoid overfitting, the training 
should be stopped when it either reaches the maximum number of 1000 epochs or its 
performance gradient drops below a minimum value of 10
-6
.  
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Table 5.3 Nodal predictive accuracy of entire marker set and its different subsets 
assessed by MLP  
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
1 51 55 52 44 
2 51 55 52 47 
3 54 63 62 34 
4 56 59 58 47 
5 56 59 58 42 
6 56 59 58 37 
7 56 59 58 37 
8 56 59 58 29 
9 52 57 56 35 
10 51 57 56 34 
11 52 57 56 35 
12 52 57 56 34 
13 52 57 56 31 
14 51 57 56 39 
15 51 57 56 32 
16 53 57 55 42 
17 54 59 57 34 
18 54 59 57 35 
19 50 58 59 32 
20 50 58 59 35 
21 55 58 61 31 
22 56 52 64 21 
23 56 52 64 29 
24 56 52 64 23 
25 56 52 64 29 
26 54 52 66 18 
27 54 59 62 24 
28 54 52 58 26 
29 54 52 61 31 
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Table 5.3 continued  
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
30 54 52 59 34 
31 58 60 63 29 
32 51 51 65 24 
33 54 51 68 16 
34 54 51 61 27 
35 52 52 58 34 
36 52 52 56 29 
37 52 52 63 21 
38 52 52 68 32 
39 52 52 58 29 
40 52 52 68 26 
41 54 59 62 27 
42 54 54 68 13 
43 56 51 66 11 
44 56 51 61 15 
45 55 50 64 11 
46 55 50 59 24 
47 55 50 62 11 
48 52 56 58 8 
49 52 56 61 13 
50 52 56 69 8 
51 52 56 57 11 
52 51 53 66 10 
53 50 55 64 34 
54 52 53 63 19 
55 50 53 68 5 
56 54 52 65 11 
57 52 52 60 8 
58 52 55 65 6 
59 51 53 66 3 
 
127 
 
Table 5.3 continued  
Group Number Sensitivity (%) Specificity (%) 
Test Accuracy 
(%) 
Apparent Error 
(%) 
60 51 56 64 3 
61 51 54 63 10 
62 50 50 67 5 
63 53 51 68 2 
 
Predicting the nodal involvement using different combination of markers for the 
MLP manifests almost the same trends and relationships between markers as the 
PNN. From Table 5.3, p53 achieves the highest accuracy among individual markers. 
Similar to the PNN results, the highest accuracy in MLP results is 69%. 
Nevertheless, the combination that achieves this accuracy is different from the PNN. 
This combination includes tumour size, ER, p53 and age while the combination in 
the PNN with highest accuracy include tumour size, ER, Ki-67 and age. This implies 
that the PNN and the MLP may discover different aspects of relationships between 
markers due to their different approaches to pattern classification. Overall, the PNN 
obtains higher accuracy in most combinations. 
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5.5. Choosing the efficient marker combination   
For comparing the PNN and the MLP results, 19 marker groups that yield the highest 
accuracy among all marker groups for both the PNN and the MLP are selected. The 
results for these groups are tabulated in Table 5.4, where the first column displays 
the marker groups referring to the marker groups defined in Table 5.1. All 19 
selected combinations in Table 5.4 obtain accuracies above 66% for the PNN and 
above 56% for the MLP.  The relation of markers in these best marker combinations 
will be further investigated and discussed in the next chapter. 
 
Table 5.4 The comparison of nodal predictive accuracy of selected marker groups 
assessed by the PNN and the MLP 
Group 
Number 
Method  
Sensitivity 
(%) 
Specificity 
(%) 
Test 
Accuracy 
(%) 
Apparent 
Error 
(%) 
17 
PNN 67 58 66 19 
MLP 54 59 57 34 
22 
PNN 62 52 67 11 
MLP 56 52 64 21 
26 
PNN 70 50 67 13 
MLP 54 52 66 18 
32 
PNN 60 53 65 13 
MLP 51 51 65 24 
33 
PNN 60 58 68 11 
MLP 54 51 68 16 
38 
PNN 52 58 67 15 
MLP 52 52 68 32 
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Table 5.4 continued  
Group 
Number 
Method  
Sensitivity 
(%) 
Specificity 
(%) 
Test 
Accuracy 
(%) 
Apparent 
Error 
(%) 
40 
PNN 50 66 67 18 
MLP 52 52 68 26 
42 
PNN 65 53 67 11 
MLP 54 54 68 13 
43 
PNN 63 53 69 11 
MLP 56 51 66 11 
50 
PNN 60 55 67 13 
MLP 52 56 69 8 
52 
PNN 65 55 66 11 
MLP 51 53 66 10 
54 
PNN 61 62 68 16 
MLP 52 53 63 19 
55 
PNN 64 53 69 8 
MLP 50 53 68 5 
56 
PNN 55 51 68 3 
MLP 54 52 65 11 
58 
PNN 55 51 67 5 
MLP 52 55 65 6 
59 
PNN 53 52 67 5 
MLP 51 53 66 3 
61 
PNN 66 57 67 8 
MLP 51 54 63 10 
62 
PNN 52 65 67 10 
MLP 50 50 67 5 
63 
PNN 59 52 67 5 
MLP 53 51 68 2 
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Comparing the sensitivity and the specificity results obtained by the PNN and the 
MLP, it is evident that the PNN can achieve better prediction for both cases. This 
difference is more noticeable in the sensitivity results which establish the PNN as a 
good choice compared the MLP when a high sensitivity is the target. 
 
5.6. Summary  
The experimental results have been presented in this chapter for the three main 
sections of the study: 1) investigating the reliability of different error estimation 
methods, 2) the comparison of the PNN classification results against the MLP and 3) 
choosing the best marker combinations.  
Section 5.3 has covered the experiments planned to investigate the reliability of 
different error estimation methods for the designed ANNs in this study. The results 
prove the low variability of the .632 bootstrap in comparison with the CV and 
holdout methods. This low variability guarantees the reliability of the network 
evaluation obtained by .632 bootstrap. The high variability in holdout and CV 
methods implies that reporting only the best results could be considerably misleading 
in cancer studies. This renders the reliability of the studies employing the holdout 
and CV methods for ANN’s error estimation debatable. 
The results of the PNN and the MLP including their accuracy, sensitivity, specificity 
and apparent error have been computed and compared in section 5.4. These results 
confirm the superiority of the PNN in obtaining more accurate results. Moreover, the 
sensitivity and specificity of the PNN are higher or close to that of the MLP. 
Nevertheless, the apparent errors obtained from the PNN are only slightly different 
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from the MLP. This can prove that the degree of generalisation of the PNN is 
comparable with that of the MLP. 
Section 5.5 has presented the best results obtained by the network in the same table 
to provide a better understating and analysis of the two ANN results by adding the 
best marker combinations. These results will be the subject of further investigation 
and discussion in the next chapter which is dedicated to the comprehensive 
discussion, detailed explanation and further analysis of the results.  
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Chapter 6 
6. Discussion and analysis  
6.1. Introduction  
The main steps in design of a pattern classifier system are: feature selection, 
classifier design and classification error estimation. All these steps should be 
designed considering the size, dimensionality and complexity of the available data in 
order to achieve an optimum pattern classification system which yields maximum 
accuracy.  
In this study, the aim was to classify breast cancer data and to estimate classification 
accuracy of the designed classifier. Feature selection has not been a direct aim of the 
study as it considered all feature combinations to investigate each feature potential in 
output classification. Therefore, the research focused on two stages of pattern 
classification system design; namely classifier design and classification error 
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estimation considering the limitations of the available dataset – small sample size 
and high complexity. The stages involved in designing a pattern classifier are shown 
in Figure 6.1, where the stages that this is focusing on are shown in grey boxes.  
 
 
 
 
 
 
 
Figure 6.1:  Stages involved in designing a pattern classifier. The stages focused 
on in this study are shown in grey. 
 
The methods employed to achieve these aims and the simulation results were 
explained in the previous chapters. The current chapter discusses a novel application 
of PNN in breast cancer prediction. The PNN has been designed and developed 
during the period of this study based on all the available markers and the criteria  for 
achieving high accuracy.  The breast cancer outcome in this thesis was chosen 
because of the significant role of the presence of tumour in the ALNs in medical 
decision making according to the medical literature [70]. And yet, previous research 
indicates the lack of agreement on a combination of predictive markers for accurate 
Feature Selection 
Classifier Design 
(Considering small sample size and 
high data complexity) 
Classification Error Estimation 
(Considering small sample size) 
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nodal status prediction that can replace the invasive procedures such as surgery and 
SLNB [7, 115]. 
 
Small sample size and complex nonlinear input-output relationship are common 
problems in predicting the ALN metastasis in breast cancer. Defining an adjuvant 
therapy is largely dependent on the prediction of nodal metastasis to the ALNs which 
is currently carried out through invasive procedures such as surgery or SLNB. Since 
many biomarkers, obtained in a non-invasive manner, have been identified to be 
related to the state of nodal involvement in breast cancer, it is advantageous to 
design a classifier which can classify patients using the non-invasively acquired data. 
For this purpose, the designed classifier should be able to capture the complex 
nonlinear input-output relation while avoiding overfitting to the available data. This 
necessitates designing the classifier with all available cases, and then to evaluate the 
generalization ability of the designed classifier using a resampling method.  
In this study, the PNN has been employed as a platform to predict the state of nodal 
involvement in breast cancer patients based on tumour size and five biomolecular 
markers as well as their different combinations. An MLP neural network was also 
designed for this application as a benchmark method to be compared against the 
PNN results. The two ANNs’ results were obtained by .632 bootstrap method for a 
reliable error estimation. For a clear investigation of results, the discussion in this 
chapter is divided into four parts. The reliability of error estimation is investigated in 
the first part. The two following parts contain the comparison of two ANNs and the 
analysis of results in terms of biomarkers’ prediction potential respectively. The last 
part of discussion is dedicated to explain how the disadvantages in previous studies 
have been addressed in the current work. 
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6.2. Reliability of Network Evaluation  
6.2.1. Bias 
The bias of an error estimation method for a classifier is measured form the 
difference between its output and the true error. Computing the true error requires 
testing the network on the whole population. This is not possible for practical 
applications like DSSs since the available data are always limited. Nonetheless, it is 
possible to measure the bias of different error estimation methods by generating data 
assuming specific distributions for each class. In this way, the estimated and the true 
error of a classifier can be compared by testing the classifier for a limited and for a 
large sample size. This has been previously carried out by Sahiner et al. [28] to 
compare the bias of different error estimation methods. Their focus was on a 
particular application for medical diagnosis, with small sample sizes and the 
conclusion of the superiority of the resampling methods including .632 and .632+ 
bootstrap over other resampling methods.  
It should be mentioned that .632 bootstrap can also suffer from optimistic bias in the 
case of strong overfitting (0% apparent error). Therefore, .632+ bootstrap was 
proposed to avoid this problem by adaptively adjusting the weights in .632 bootstrap 
[75]. However, .632+ bootstrap may result in overcorrecting the bias of the .632 
bootstrap. Hence, .632 bootstrap is more reliably employed with methods with 
apparent errors of greater than 0% [75]. In this study, apparent errors of higher than 
5%  were obtained where the best prediction results  were achieved from the groups 
with apparent errors of higher than 8%. 
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6.2.2. Variance  
For reliable comparison of the results obtained by the PNN and the MLP, it was 
important to use an accurate and reliable error estimation method. This is especially 
important in the application of ANNs in cancer prediction using patient biomarkers 
due to small sample sizes available in this field. 0.632 bootstrap was therefore 
employed to estimate the error of the two ANNs. This resampling technique was 
chosen for its low variance compared to the widely used cross validation method 
[116]. This was investigated in this study by comparing the variance of AUCs 
obtained by .632 bootstrap, 5-fold cross validation and holdout methods. It is evident 
from the results in Figure 5.1 to 5.4 that 5-fold cross validation and holdout methods 
have a significantly higher AUC variance than the .632 bootstrap AUC variance. The 
boxplots in these figures illustrate the high variability and the existence of outliers 
when computing the AUC using holdout method. This variability is reduced when 
using the 5-fold CV and is the lease with the use of .632 bootstrap. This is true of all 
combinations regardless of the employed network (MLP or PNN), input dimension 
(Figures 5.1 and 5.3) or the input markers (Figures 5.2 and 5.4).  
The .632 bootstrap low variance results from the fact that the randomness in CV 
training and test sets is eliminated by using 50 bootstrap replications of the training 
data. In addition, misclassification error rate computed using .632 bootstrap is fairly 
unbiased and hence more reliable compared to apparent error estimator which suffers 
from low bias [28, 75, 117]. The low bias in apparent error happens as the same data 
employed for training the network is then used to test it.  
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6.3. Artificial neural network performance 
analysis  
The MLP and the PNN are both trained in a supervised manner (i.e. the 
corresponding output of each input pattern is available to the network during the 
training course). The fundamental difference between the MLP and the PNN lies in 
their different data analysis approaches applied to perform the classification task. 
This can be represented by the dichotomous statistical pattern classification 
approaches denoted by Jain et al [118] as “Density-Based” and “Geometric” 
approaches. These methods discriminate based on whether the decision boundary is 
derived indirectly from the PDF estimation of training data or directly from the 
training data. The PNN data analysis approach to perform the classification task can 
be represented by the “Density-Based” statistical pattern classification approach. 
This method discriminates based on deriving the decision boundary indirectly from 
the PDF estimation of training data. Hence, in the PNN data classification approach, 
approximating the underlying distribution of data by estimating the PDF is targeted. 
Alternatively, data classification in the MLP is geometric which is carried out by 
handling the numerical data directly. The MLP performs pattern classification by 
constructing the decision boundaries based on the training data and optimising a cost 
function.  
MLP has been widely used in cancer studies in spite of some common drawbacks 
such as network complexity, optimisation of numerous network variables and 
random weight initialisation. The PNN maintains unique advantages which makes it 
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an alternative ANN structure to the MLP for some classification problems. These 
advantages include: 
- its rapid training capability which makes it many times faster than the 
SCG algorithm and guaranteed convergence to the optimal Bayes 
classifier by choosing the most probable classification among all 
possible classes;  
- it is easily modified by adding new training data and hence is 
compatible with online applications, unlike the SCG algorithm which 
needs to be retrained for any modification in the training data;  
- the PNN outputs are interpretable in the sense that the inputs can be 
characterized by their effectiveness in making the output decision 
[119]. 
On the other hand, the PNN requires a large amount of memory to run, as all the 
training data needs to be stored during the PNN training process [24]. This is not an 
issue in small sample size classification problems as the number of available data for 
training is limited and hence, the amount of required memory to store the data does 
not pose a problem. 
In addition, the prior knowledge is employed in the PNN in combination with the 
data to classify a new input.  This prior knowledge is in the form of the relative 
frequency of the output categories in the data.  
PNN also addresses two main practical difficulties in the Bayesian methods. The 
first difficulty in Bayesian methods is the requirement of having knowledge about 
the data distributions. In classification problems, these distributions are not known 
and they must be estimated from the available data. The conventional statistical 
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classification methods estimate these probabilities in a parametric manner, i.e. by 
making assumptions about the form of the underlying distributions. Parametric 
density estimation methods assume a unimodal density distribution with one local 
maximum. However, most practical classification problems involve data with 
multimodal densities.  In order to model densities with more than one local 
maximum, PDFs can be estimated in a nonparametric manner. Nonparametric 
density estimation methods make no assumption about the underlying distribution of 
the data and therefore, they can be exercised for arbitrary distributions [44].  
Another advantage of the PNN over the MLP is the use of prior probability. The 
estimation of prior in classification problems can be simply obtained from the 
relevant frequency of each category.  
Generally, the PNN performed more accurately than the MLP. The mean accuracy of 
19 chosen combinations obtained by the PNN was more than the mean obtained by 
MLP by 4%. PNN attained the best accuracy of 69%, the best sensitivity of 67% and 
specificity of 66%.  
Better results obtained by PNN compared to MLP can be explained by the 
fundamental characteristic of the learning procedures in the PNN and the MLP. Both 
network structures use supervised learning wherein the aim is to obtain an optimum 
set of weights in the network that best describes the relationship between a set of 
input-output patterns and can be generalized for predicting new patterns. Learning in 
the PNN was carried out by employing prior knowledge about the data population 
and defining weights using training data. This prior knowledge  was implemented in 
the PNN in the form of the ratio of the frequency of training samples from each class 
in addition to modelling the probability densities of the training patterns using 
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Gaussian kernel. Classification in PNN was then performed using the Bayesian 
approach to describe the relationship between input-output patterns by computing the 
posterior probability. In the MLP, training was carried out by minimising a cost 
function derived from the training data based on maximum likelihood approach. 
Therefore, learning in the MLP included an iterative procedure, as described in 
section 4.2., which uses only the information provided by the training data to define 
an optimum set of weights. Accordingly, PNN has an advantage over the MLP in 
that it uses both prior knowledge and training data to achieve classification.  
Comparing the output apparent error of different marker combinations, it was 
observed that although the combination including all markers obtained the lowest 
apparent error of 5% in the PNN, its test accuracy was not as high as some of the 
other combinations. The fact that the inclusion of all the variables offered the best 
design accuracy indicated that each marker makes a contribution to the classification 
process and yet some specific patterns of relationship emerge between the input and 
outputs that lead to a poor prediction, which probably reflects the relative 
significance of the variables engendered by the interaction between them.   
 
6.4. Predictive Value of Markers 
Establishing the efficacy of the markers through grouping can provide good 
indications of the relative contribution of each marker to outcome prediction and the 
relationships it may have with other potential markers.  
Several important and novel features’ combinations have emerged from the present 
investigation. Although tumour markers have been used for many years, an ANN 
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seems capable of not only judging the weights or significance of individual makers 
to disease progression, but also, as shown in this study, it  provides a decision 
making capability that takes into account the interactions between the signalling  by 
different markers that indeed governs the route of tumour progression.  
With the PNN neural network, the best prediction accuracy of 69% was obtained by 
a combination of ER, p53, Ki-67 and age with and without PR. Steroid receptor 
status and the degree of p53 expression or other proliferation markers have often 
offered fertile grounds for debate as to whether they could serve as independent 
markers of cancer progression and prognosis. Historically, steroid hormone receptor 
status has received much attention from the clinical and research faculty in this 
regard. The present work sheds light on the relevance of ER/PR in assessing cancer 
progression. The interaction between signalling by the steroid hormones through 
their respective receptors is evident from the finding in this study that omission of 
ER or PR individually does not make a sizeable effect in the predictive ability. Since 
ER in an active functional state can induce the expression of PR, it follows that the 
presence of either marker would suffice to provide the biological factor required for 
asserting predictive ability. Omission of both ER and PR markedly reduces the 
prediction scores in PNN. Overall, the conservative conclusion is that ER/PR might 
influence prediction as independent factors.  
Individually, the markers have low predictive ability in the range of 51-61% in PNN. 
It is the success achieved by combining different markers which deserves special 
emphasis here. Tumour size appears from this analysis to be an important contributor 
to the predictive ability, for its omission resulted in a marked reduction in predictive 
accuracy. This is possibly related to the higher invasive ability of larger tumours 
which attributes to the greater proliferative pressure within the tumour.  
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The cell cycle regulator p53 is mutated or lost in a majority of human cancers. Hence 
the debate has addressed issues relating to the p53 expression as an aid in assessing 
tumour behaviour. The results of the study show that the omission of p53 and/or Ki-
67 leads to approximately 5% loss in predictive accuracy. This could indicate the 
possibility that p53 might not be an independent marker of progression.  
Finally, one important line of reasoning that this investigation seems to generate and 
highlight is whether ER/PR signalling interacts with the p53 signalling pathway. As 
noted earlier, ER and PR might be able to compensate for omission of p53, but the 
question that needs to be answered is whether ER and PR make an independent 
contribution to the process of tumour progression. An early approach to this question 
was to test if resistance to tamoxifen was related to p53 over expression, although 
refractoriness of breast
 
cancer cell lines to tamoxifen can be due to other factors such 
as the expression of HER2. In breast cancer, p53 did not appear to be significantly
 
associated with response to tamoxifen, although tumours over expressing p53
 
protein 
were more aggressive and the patients showed poorer survival [120]. Loss of ER 
brought about by methylation in 26% and abnormalities of p53 pathway in 53% of 
cases was found in an investigation to discover whether in endometrial cancers ER 
and p53 pathways were inter-related [121]. However, there was no discernible link 
between the loss of ER and abnormalities in p53 signalling. On the other hand, 
others have suggested some correlation between p53 and ER signalling. Ovarian 
tumours have been reported to show abnormalities in mdm2 and p14ARF, both 
related to p53 signalling, and abnormalities. ER has been implicated in the regulation 
of this p14ARF-MDM2-p53 pathway [122]. Kang [123] has reported that mutations 
of p53 results in increased expression of pS2, a downstream target of ER. This effect 
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could be abolished by inhibiting a p53-directed signalling system involving the 
extracellular signal-regulated kinases.  
The best prediction obtained from the combination of all markers excluding tumour 
size maintains a low error test while upholding reasonable apparent error. Moreover, 
this subset showed a sound value for sensitivity which was very low in other 
combinations. Therefore, this subset was used for comparison with other subsets. 
Omission of age from this best performing set markedly increased the apparent error, 
albeit with reduction also in the test accuracy. In general, when age is excluded, the 
accuracy results are lower than when it is included. In relation to the other markers, 
age produced strong prediction results.    
 
6.5. How disadvantages in the previous 
models are addressed  
ANNs have been employed in the field of medical diagnosis for nearly 20 years . 
They are suitable for both classification and regression, are tolerant to noisy inputs 
and their structure and connection weights can be configured such that they will be 
able to represent Boolean functions (AND, OR, NOT). However, the widespread use 
of them is sometimes criticized due to some common drawbacks such as the 
limitation of understanding the algorithm structure constructed by the network 
connections, large number of parameters which may result in overfitting and 
difficulty in defining an optimal network structure (optimal number of hidden layers 
and nodes) [50].  
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In addition, the network must be able to predict the outcome for new data which 
might be slightly different from the training data. Therefore, constructing the 
network such that it can only predict the training data perfectly is not desirable. In 
order to estimate the generalization ability of the network, it is important to estimate 
the error of the designed ANN for new data. However, reliable error estimation 
under the constraint of small sample size is another issue that has been neglected in 
many ANN-based studies for cancer prediction. Below is a discussion of how these 
drawbacks have been addressed in this study. 
6.5.1. Overfitting  
Overfitting is one of the main issues in training the MLPs.  In practical applications 
and especially in the field of medical diagnosis, the dataset includes limited number 
of samples. Additionally, this should be further partitioned for the training and test 
purposes to provide independent evaluation of network ability for the prediction of 
new samples. MLPs normally perform well for predicting the training data but they 
provide poorer predictions for the test data. The poor generalisation ability of the 
ANNs results from overfitting the network parameters to the training data.  
As mentioned in chapter 2, CV can be employed to detect when the network starts to 
overfit during the training process and hence, avoiding the overfitting by 
discontinuing the training process from that point. However, CV is not an optimum 
method as a part of the data is kept for the validation purpose and hence, the network 
is trained only with a part of data. This is especially problematic with small datasets 
as the patterns in the data must be unveiled only with a part of the small data.  
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In this study, the overfitting in the MLPs was obviated by employing a PNN 
structure which maintains small number of free parameters to be estimated. Among 
different supervised ANN structures, PNN has the least number of free parameters 
with only one parameter to estimate. This characteristic allows the PNNs to be 
employed in conjunction with small data sizes while the MLP was limited in this 
manner. The large number of free parameters in MLPs complicates choosing an 
optimised network structure for the problem at hand. Main free parameters of MLPs 
include number and size of hidden layers, hidden layer transfer function, cost 
function employed for training the network and initial weights and biases. 
Unfortunately, there is no agreement on a definite method for choosing an optimum 
amount for these parameters. In most studies, these parameters are decided by 
experiment [118]. Nevertheless, the PNN’s only free parameter, the spread, was 
defined in this study by Silverman’s rule thumb that has been proven to provide a 
good approximate for the spread of the data while evading over fitting to the training 
data [124]. 
6.5.2. Error estimation  
Most ANN applied to diagnostic classification problems suffer from biased 
estimation of the classification error [20]. The random division of data (holdout 
method) has been used in most studies as an error estimation method for MLP. 
However, holdout method results in a high variance in the output results and can 
become misleading by reporting only the best achieved results in multiple runs of 
network with different random selections of training and test sets.  On the other 
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hand, unbiased estimation of error via cross validation results in the high variability 
of estimated errors by differently partitioning the data. In this study, a reliable 
estimation of network classification error was achieved by employing .632 bootstrap 
method. In addition, this method maintains a low bias which makes it an apt choice 
to be employed in conjunction with small medical data sizes. Moreover, the 
limitation of small sample sizes can be obviated using .632 bootstrap resampling 
method to generate new training and test sets with the same distribution as the 
original data.  
6.6. Summary  
The main three sections of results presented in the previous chapter were discussed 
in this chapter in detail. The first section covered the comparison between different 
error estimation methods and the reasoning for the superiority of .632 bootstrap over 
CV and holdout methods. The comparison results of the PNN and the MLP were 
elaborated in the second part of this chapter. While both methods maintain some 
unique advantages, the PNN was more suitable for the application of ANL 
metastasis prediction and performed more accurately than the MLP. The predictive 
potential of the markers together with some medical literature were also discussed. 
The best prediction was obtained from the combination of all markers excluding 
tumour size which demonstrates that including more markers does not necessarily 
lead to higher accuracies. Some of the gaps in the application of ANNs in cancer 
studies and how they were addressed in this research were covered in the last section 
of this chapter. The next chapter entails the main conclusions of the study and how it 
contributes to a wider context of research. 
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Chapter 7 
7. Conclusions and future work  
7.1. Research contributions  
Much research has been devoted to the study of ANNs’ application in cancer 
prediction. In addition, there is background literature available on the reliability of 
resampling error estimation methods used in conjunction with ANNs [28]. However, 
this is the first study of its kind that investigates the application of PNN in the 
prediction of ALN metastasis using a reliable error estimation method to obviate the 
issue of small sample size. The developed approach is capable of synthesizing and 
integrating specific biomarkers of the breast tumour in order to carry out complex 
evaluations and present the results to the clinicians in a timely manner. Moreover, 
this study offers explanation, comparison and performance assessment of two feed-
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forward neural networks with application of predicting the state of nodal 
involvement in breast carcinoma.  
Three conclusions can be drawn from the present series of experiments, one relating 
to the reliability of ANNs in conjunction with small datasets. The second is 
regarding the networks’ architectures and the analysis of PNN and MLP potential for 
the present application.  The third is regarding the markers’ significance in cancer 
prognosis.  
Generally, ANNs offer the possibility to investigate the complex relationships 
between individual markers affecting tumour progression and prognosis. However, a 
judicious choice of an error estimation method for the evaluation of ANN outcome 
leads to significant improvement in the reliability of outcome analysis. From the 
results and comparisons in this study, it is clear that the .632 bootstrap method gives 
a reliable validation of network accuracy compared to holdout and 5-fold CV. 
Besides, the .632 bootstrap approach makes it viable to exploit all the available data 
for training purpose that is especially advantages in medical studies with the 
constraint of small sample size. High error estimation reliability offered by .632 
bootstrap allows ANN systems to maintain a good generalization and provide 
reliable analysis in limited datasets.   
Among the two ANN structures considered in the study, the results show that for the 
present application, the PNN performs better than the MLP by providing better 
prediction accuracy, especially when a large number of markers are present. The 
main disadvantage of the PNN over MLP is that it requires a large number of hidden 
units as the size of hidden layer in the PNN depends on the number of input patterns. 
This drawback is negligible in most medical applications as the datasets in this 
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domain usually contain only a limited number of patterns due to the intricacy in 
measuring the biomarkers. On the other hand, the training time required by the PNN 
is considerably shorter than MLP. Although the SCG algorithm employed for 
training the MLP is a relatively fast method compared with the BP algorithm, it still 
needs several iterations to find the minimum of the error surface and provide an 
optimum output prediction. The PNN method only needs a single forward iteration 
for the training process which makes it a considerably faster method than the MLP. 
An overview of the two ANN structures has led to the conclusion that in general 
terms, the PNN network provides better prediction outcome while it seems to uphold 
the major findings with the MLP network in terms of the importance of tumour size 
and p53 as factors that influence tumour progression. 
With regard to the markers’ prognostic significance, the full set of markers is 
required to provide the highest classification accuracy in the training process. 
However, the subset including ER, p53, Ki-67 and age results in a better test 
accuracy for both the MLP and the PNN. Although individual markers achieve low 
predictive scores, certain combinations do indicate marked benefit in terms of 
prediction of nodal involvement. Combination of tumour size appears from this 
analysis to be an important contributor to the predictive ability possibly reflecting the 
higher invasive ability of larger tumours. The omission of Ki-67 expression results in 
a slight loss in predictive accuracy suggesting Ki-67 might not be an independent 
marker of progression. 
The present work has clearly demonstrated that the steroid signalling might be 
compensating for the omission of p53/Ki-67, for the omission of both ER and PR 
markedly reduces predictive accuracy. This confirms the importance of ER and PR 
in assessing progression and also provides evidence for the interaction between 
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signalling by these steroids. The present work suggests that ER/PR might 
compensate for the omission of p53, and further there are clear indications here that 
ER and p5  do not greatly affect each other’s influence on predictive outcome and 
therefore on disease progression.   
It is  recommend that the classification accuracy of this panel of markers possesses 
significant potential for predicting nodal spread of breast cancer in individual 
patients.  The accuracy which seems to flow from the biological features that define 
disease progression should greatly reduce the need for adopting invasive procedures, 
and in this way reduce the post-operative stress and associated morbidity experience 
by patients. Furthermore, it is needless to reiterate the potential reduction of the time 
lag between investigation and decision making in patient management. 
 
7.2. Future work  
This study meets the criteria for a study design in medical diagnosis including a 
good structure and reliable validation. Even so, there are certain aspects of the study 
that can be improved given more time and resources. These mainly include 
employing the PNN results for further interpretation and utilising a larger dataset for 
the design and validation of the study.  
- The present work has clearly demonstrated the superiority of the PNN 
over conventional statistical and machine learning methods and also 
the commonly employed MLP. This superiority comes from the 
special properties of the PNN including fast training, easily 
modifiable structure and meeting Bayesian optimality in 
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classification. In this study, these unique characteristics are proved to 
significantly improve the accuracy and reliability of breast cancer 
prediction. As mentioned before, the improvement in the reliability is 
achieved by employing the bootstrap evaluation which is possible to 
apply in practice due to the fast training of the PNN. One important 
characteristic of the PNN which has been mentioned in this study is 
its interpretability in terms of the output probability. Using the output 
probabilities for further interpretation of the results is a future aim of 
the study as it may shed more light on the potential of each biomarker 
in prediction. 
- Regarding the breast cancer data, as the availability of data is limited 
in this domain, collection of more data for further substantiating the 
results would be sought in future. Upon validating the results with a 
larger sample of patients, the proposed techniques would be 
applicable in practice for breast cancer diagnosis. In addition to the 
size of the data, the performance of ANN largely depends on the 
measurement accuracy of the employed markers for classification. 
Those biomarkers which need a human observer for quantification are 
prone to provide poor data quality given an inexpert observer. 
Therefore, obtaining all biomarkers in an automatic fashion is sought 
in the future studies. 
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